UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 1of 39STATISTICA L AN ALYSIS PLAN 
Study: PD0049
Product: Rotigotine transdermal system
A MULTICENTER, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE IMPACT OF 
USING WEARABLE DEVICES IN ADDITION TO STANDARD CLINICAL  PRACTI CE ON 
PARKI NSON’S SUBJECT SYMPTOMS MANAGEMENT
SAP/Amendment Number Date
Final SAP 14 Jun 2017
Amendment 1 31 Jan 2018
Confidential ity Statement
Confidential
This document is the property of UCB and may not –in full or in part – be passed on, reproduced, 
published ,or otherwise used without the express permission of UCB.REDACTED COPY 
This document This document is the property of UCB and may not 
document This document is the property of UCB and may not 
document cannot cannot be used to support any marketing 14 Jun 2017
marketing 14 Jun 2017
31 Jan
marketing 31 Jan 2018
marketing 2018authorization application NSON’S SUBJECT SYMPTOMS MANAGEMENT
application NSON’S SUBJECT SYMPTOMS MANAGEMENT and -ARM STUDY TO EVALUATE THE IMPACT OF 
and -ARM STUDY TO EVALUATE THE IMPACT OF 
CES IN ADDITION TO STANDARD CLINICALand CES IN ADDITION TO STANDARD CLINICAL
NSON’S SUBJECT SYMPTOMS MANAGEMENT and NSON’S SUBJECT SYMPTOMS MANAGEMENTany -ARM STUDY TO EVALUATE THE IMPACT OF any -ARM STUDY TO EVALUATE THE IMPACT OF 
CES IN ADDITION TO STANDARD CLINICALany 
CES IN ADDITION TO STANDARD CLINICALextensions or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 2of 39TABLE OF CONTENTS
LIST OF ABBREVIATIONS....................................................................................................5
1 INTRODUCTION .............................................................................................................7
2 PROTOCOL  SUMMARY.................................................................................................7
2.1 Study  objectives .................................................................................................................7
2.1.1 Primary objectives .................................................................................................7
2.1.2 Other objectives .....................................................................................................8
2.2 Study variables...................................................................................................................8
2.2.1 Efficacy  variables ..................................................................................................8
2.2.1.1 Primary  efficacy  variables ...........................................................................8
2.2.1.2 Other efficacy  variables...............................................................................9
2.2.2 Safety  variable .......................................................................................................9
2.3 Study  design and conduct ................................................................................................10
2.4 Determination of sample size...........................................................................................133 DATA ANALYSI S CONSI DERATIONS ......................................................................13
3.1 General presentation of summaries and analys es............................................................13
3.2 General study level definitions ........................................................................................14
3.2.1 Analy sis time points ............................................................................................14
3.2.1.1 Relative Day ..............................................................................................14
3.2.1.2 End date of the Treatment Period..............................................................14
3.2.2 Study  periods .......................................................................................................14
3.2.3 Mapping of assessments performed at Earl y Withdrawal Visit ..........................15
3.2.4 Rescreening..........................................................................................................15
3.3 Definition of Baseline values...........................................................................................153.4 Protocol deviations...........................................................................................................153.5 Analy sis sets.....................................................................................................................15
3.5.1 Enrolled Set .........................................................................................................153.5.2 Safety  Set .............................................................................................................15
3.5.3 Full A nalysis Set ..................................................................................................15
3.5.4 Per Protocol Set ...................................................................................................16
3.6 Treatment assignment and treatment groups ...................................................................163.7 Center pooling strategy ....................................................................................................16
3.8 Coding dictionaries ..........................................................................................................16
3.9 Changes to protocol-defined anal yses..............................................................................16
4 STATISTICAL/ANALYTI CAL ISSUES .......................................................................16
4.1 Adjustments for covariates...............................................................................................164.2 Handling of dropouts or missing data..............................................................................174.3 Interim anal yses and data monitoring ..............................................................................17REDACTED ................................
REDACTED ................................
................................
REDACTED ................................
3.2.1.2 End date of the Treatment Period................................
REDACTED 3.2.1.2 End date of the Treatment Period................................
................................REDACTED ................................
Mapping of assessments performed at EarlREDACTED Mapping of assessments performed at EarlCOPY ................................
COPY ................................
................................
COPY ................................
This document 3.8
document 3.8
3.9
document 3.9cannot Treatment assignment and treatment groups
cannot Treatment assignment and treatment groups
cannot Center pooling strategycannot Center pooling strategybe Per Protocol Setbe Per Protocol Setused Safety
used Safety  Set ................................
used  Set ................................ Safety  Set ................................ Safety
used Safety  Set ................................ Safety
Full Aused Full Ato Enrolled Set
to Enrolled Set
 Set ................................to  Set ................................support 3.4 Protocol deviations................................
support 3.4 Protocol deviations................................
................................
support ................................
Enrolled Set support Enrolled Setany Definition of Baseline values
any Definition of Baseline values ................................
any ................................
3.4 Protocol deviations................................ any 3.4 Protocol deviations................................marketing ................................
marketing ................................
Mapping of assessments performed at Earl
marketing Mapping of assessments performed at Earl
................................
marketing ................................authorization ................................
authorization ................................ ................................
authorization ................................
................................
authorization ................................ ................................
authorization ................................
................................
authorization ................................
3.2.1.2 End date of the Treatment Period................................
authorization 3.2.1.2 End date of the Treatment Period................................application ................................
application ................................
................................
application ................................
................................
application ................................
................................application ................................and ................................
and ................................ ................................10
and ................................10any ................................any ................................
................................10any ................................10extensions ................................
extensions ................................
................................
extensions ................................
................................extensions ................................or ...................8or ...................8variations .....8variations .....8
...................8variations ...................8thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 3of 394.4 Multicenter studies...........................................................................................................17
4.5 Multiple comparisons/multiplicity ...................................................................................17
4.6 Use of an efficacy  subset of subjects ...............................................................................17
4.7 Active-control studies intended to show equivalence......................................................184.8 Examination of subgroups ...............................................................................................185 STUDY POPUL ATION CHARACTERI STICS .............................................................18
5.1 Subject disposition ...........................................................................................................18
5.2 Protocol deviations...........................................................................................................186 DEMOGRAPHI CS AND OTH ER BASELINE CHARACTE RISTICS ........................19
6.1 Demographics ..................................................................................................................19
6.2 Other Baseline characteristics..........................................................................................19
6.3 Medical history  and concomitant diseases .......................................................................19
6.4 Prior and concomitant medications..................................................................................197 MEASUREMENTS OF TREATMENT COMPLIANCE...............................................208 EFFI CACY ANALYSES ................................................................................................20
8.1 Statistical analy sis of the primary  efficacy  variables .......................................................20
8.1.1 Derivations of primary  efficacy  variables ...........................................................20
8.1.1.1 Unified Parkinson’s Disease Rating Scale Part III....................................208.1.1.2 Kinesia-ONE variables..............................................................................208.1.1.3 Number of Neupro dose changes ..............................................................21
8.1.2 Primary anal ysis of the primary  efficacy  variables .............................................22
8.1.3 Secondary anal yses of the primary  efficacy  variables .........................................22
8.1.4 Supportive and sensitivity anal yses of the primary efficacy  variables................22
8.2 Analy sis of other efficacy variables .................................................................................22
8.2.1 Kinesia- 360 motor scores ....................................................................................22
8.2.2 Parkinson’s Disease Questionnaire (PDQ-39).....................................................238.2.3 Patient Activation Measure (PAM-13)................................................................248.2.4 Unified Parkinson’s Disease Rating Scale Parts I, II, IV ....................................24
9 PHARMACOKINETICS AND PHARMACODYNAMI CS..........................................25
9.1 Pharmacokinetics .............................................................................................................259.2 Pharmacod ynamics ..........................................................................................................25
10 SAFETY ANALYSES.....................................................................................................2510.1 Extent of exposure ...........................................................................................................25
10.2 Adverse events .................................................................................................................25
10.3 Clinical laboratory evaluations ........................................................................................26
10.4 Other observations related to safety.................................................................................26
10.4.1 Weight ..................................................................................................................26
10.4.2 Other safety  variables ..........................................................................................26REDACTED Unified Parkinson’s Disease Rating Scale Part III
REDACTED Unified Parkinson’s Disease Rating Scale Part III
................................
REDACTED ................................
Number of Neupro dose changes
REDACTED Number of Neupro dose changes
is of the primary
REDACTED is of the primary
es of the primary REDACTED es of the primaryCOPY  variables ................................
COPY  variables ................................
Unified Parkinson’s Disease Rating Scale Part III COPY Unified Parkinson’s Disease Rating Scale Part III
This document 10.1
document 10.1
10.2
document 10.2cannot Pharmacod
cannot Pharmacod
SAFETY ANALYSEScannot SAFETY ANALYSES
Extent of exposurecannot Extent of exposurebe Pharmacokineticsbe Pharmacokinetics
Pharmacodbe Pharmacodused Unified Parkinson’s Disease Rating Scale Parts I, II, IV
used Unified Parkinson’s Disease Rating Scale Parts I, II, IV
PHARMACOKINETICS AND
used PHARMACOKINETICS AND
Pharmacokinetics used Pharmacokineticsto Unified Parkinson’s Disease Rating Scale Parts I, II, IV to Unified Parkinson’s Disease Rating Scale Parts I, II, IVsupport 360 motor scores
support 360 motor scores
Parkinson’s Disease Questionnaire (PDQ
support Parkinson’s Disease Questionnaire (PDQ
Patient Activation Measure (PAMsupport Patient Activation Measure (PAM
Unified Parkinson’s Disease Rating Scale Parts I, II, IVsupport Unified Parkinson’s Disease Rating Scale Parts I, II, IVany  variables
any  variables
360 motor scores any 360 motor scoresmarketing is of the primary
marketing is of the primary  efficacy
marketing  efficacy is of the primary  efficacy is of the primary
marketing is of the primary  efficacy is of the primary
es of the primary
marketing es of the primary
pportive and sensitivity anal
marketing pportive and sensitivity anal
 variablesmarketing  variablesauthorization Unified Parkinson’s Disease Rating Scale Part III
authorization Unified Parkinson’s Disease Rating Scale Part III
................................
authorization ................................
Number of Neupro dose changes
authorization Number of Neupro dose changes
is of the primary authorization is of the primary  efficacyauthorization  efficacy is of the primary  efficacy is of the primary authorization is of the primary  efficacy is of the primaryapplication ................................
application ................................
................................
application ................................
................................
application ................................
 variables ................................application  variables ................................and ................................
and ................................
................................ and ................................any ................................
any ................................
................................ any ................................extensions ........................19
extensions ........................19
..................19
extensions ..................19
..........................19
extensions ..........................19or ...........18or ...........18
........................19or ........................19variations ...........18
variations ...........18
...........18 variations ...........18thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 4of 3911 REFERENCES ................................................................................................................27
12 APPENDI CES .................................................................................................................28
13 AMENDMENT(S) TO THE STATI STICAL  ANALYSI SPLAN (SAP) (IF 
APPLICABLE) ................................................................................................................29
13.1 AMENDMENT 1 .............................................................................................................29
13.2 AMENDMENT 2 .............................................................................................................38
STATI STICAL ANALYSI S PL AN SIGNATURE PAGE.....................................................39
LIST OF TA BLES
Table 2‒1: Schedule of stud y assessments.........................................................................10
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions ................................
extensions ................................or variations .....................39
variations .....................39thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 5of 39LIST OF A BBREVIATION S
ADaM Analy sis Data Model
AE adverse event
ANCOVA analysis of covariance
APP application, application software
BMI body  mass index
BSA body  surface area
CG Control Group
CI confidence interval
cm centimeters
EG Experimental Group
EOS end of study
ES Enrolled Set
EW Early withdrawal
FAS Full Anal ysis Set
FDA Food and Drug Administration
GLNT Great Lakes NeuroTechnologies, Inc.
H0 null hy pothesis
Ha alternative h ypothesis
HLT high level term
ICF Informed Consent form
ICH International Council for Harmonization
in inches
lb pounds
kg kilograms
MedDRA Medical Dictionary  for Regulatory  Activities
PAM-13 13-Item Patient Activation Measure
PDQ -39 39-Item Parkinson’s Disease Questionnaire
PPS Per-Protocol Set
PT preferred term
Q1 first (25th percent) quartileREDACTED Food and Drug Administration
REDACTED Food and Drug Administration
NeuroTechnologies, Inc.REDACTED NeuroTechnologies, Inc.COPY 
This document P
document PAM
document AM
PDQ
document PDQcannot MedDRAcannot MedDRAbe used to support high level term
support high level term
In
support Informed Consent form
support formed Consent form
International support International any high level termany high level termmarketing NeuroTechnologies, Inc.
marketing NeuroTechnologies, Inc.
pothesis
marketing pothesis
alternative hmarketing alternative h ypothesismarketing ypothesisauthorization Food and Drug Administration
authorization Food and Drug Administration
NeuroTechnologies, Inc. authorization NeuroTechnologies, Inc.application and any extensions or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 6of 39Q3 third (75th percent) quartile
SAP Statistical Analysis Plan
SD standard deviation
SOC system organ class
SDTM Study  Data Tabulation Model
SS Safety  Set
TEAE treatment -emergent adverse event
UPDRS Unified Parkinson’s Disease Rating Scale
WHODD World Health Organization Drug dictionary
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 7of 391 INTRODUCTION
This Statistical Analysis Plan (SAP) defines the scope of statistical anal yses and provides a 
detailed description of methodology for the statistical anal yses to support the final clinical study  
report for PD0049.
The SAP is based on the clinical study protocol, dated 16 Dec 2016. The content of this SAP is in compliance with the International Council for Harmonization (I CH) 
/ Food and Drug Administration (FDA) E9 Guidance documents.
2 PROTOCOL SUMMA RY
PD0049 is a pilot study  to investigate whether motor sy mptoms in subjects with Parkinso n’s 
disease who start treatment with Neupro®can be improved b y using wearable devices. 
Specificall y, this study focuses on investigating how to optimize the evaluation of motor 
symptoms in subjects with Parkinson’s disease aiming at enabling Investigators to optimize 
subjects’ Neupro dosing regimens and ensure better patient outcomes in a timelier manner.In this stud y, 2Kinesia devices (Kinesia- ONE and Kinesia -360) will be employ ed to record 
specific motor s ymptoms. Approximately  40 subjects with Parkins on’s disease of any stage will 
be randomized (1:1 ratio) to either the Control Group or the Experimental Group. Specific motor 
tasks will be measured in all subjects with Kinesia- ONE on Day 1. In contrast to subjects 
randomized to the Control Group, subjects randomized to the Experimental Group will also use the Kinesia-360 device for home-based self-recording of their motor s ymptoms.
All subjects will start Neupro treatment at a dose of either rotigotine 2mg/24h or 4mg/24h 
(according to the disease stage of the subject), which will then be adjusted based on s ymptom 
assessment either via standard care alone (Control Group) or via a combination of standard care 
and evaluation of the recordings made available by the Kinesia wearable technologies 
(Experimental Group). The Neupro dosing regimen used in PD0049 follows standard of care, 
and is in line with the approved dosing regimen for rotigotine in the treatment of Parkinson’s disease (ie, up to 8mg/24h, depending on the stage of the disease).
PD0049 starts with in-clinic Screening activities, assessments (including recording of Baseline 
motor sy mptoms via Kinesia-One), and training in the use of Kinesia-360 devices (for subjects 
randomized to the Experimental Group only ) on Day 1, followed by  3days at home: Dur ing this 
period, subjects randomized to the Experimental Group will use the Kinesia-360 device to record 
their motor sy mptoms (on Day s 2 and 3). Subjects allocated to the Control Group will start 
treatment with Neupro preferabl y on Day 1 (but no later than Day 4); subjects allocated to the 
Experimental group will start treatment with Neupro on Day 4. There are no required visits from Week 2 up to Week 12 (Visit 2). However, Investigators and subjects in the Experimental Group 
are encouraged to discuss by  phone Kinesia -360 motor sy mptom reports and needs for an y 
changes in Neupro dosing. Subjects of either group return to the clinic for final assessments and reporting of adverse events (AEs) and concomitant medications at Week 12. The individual 
duration of study  participation may  last up to 12 weeks.
2.1 Stud y objectives
2.1.1 Primary o bjectives
The primary objectives of this study  are to:REDACTED recording of their motor s
REDACTED recording of their motor s
All subjects will start Neupro treatment at a dose of either rotigotine 2mg/24h or 4mg/24h 
REDACTED All subjects will start Neupro treatment at a dose of either rotigotine 2mg/24h or 4mg/24h 
f the subject), which will then be adjusted based on s
REDACTED f the subject), which will then be adjusted based on s
assessment either via standard care alone (Control Group) or via a combination of standard care REDACTED assessment either via standard care alone (Control Group) or via a combination of standard care 
and evaluation of the recordings made available by REDACTED and evaluation of the recordings made available byCOPY be randomized (1:1 ratio) to either the Control Group or the Experimental Group. Specific motor 
COPY be randomized (1:1 ratio) to either the Control Group or the Experimental Group. Specific motor 
ONE on Day
COPY ONE on Day
randomized to the Control Group, subjects randomized to the Experimental Group will also use COPY randomized to the Control Group, subjects randomized to the Experimental Group will also use 
recording of their motor sCOPY recording of their motor s
This document are encouraged to discuss by
document are encouraged to discuss by
document changes in Neupro dosing. Subjects of either group return to the clinic for final assessments and 
document changes in Neupro dosing. Subjects of either group return to the clinic for final assessments and 
reporting of adverse events (AEs) and concomitant medications at Week
document reporting of adverse events (AEs) and concomitant medications at Weekcannot Experimental group will start treatment with Neupro on Day
cannot Experimental group will start treatment with Neupro on Day
Week
cannot Week 2 up to Week 12 (Visit
cannot 2 up to Week 12 (Visit
are encouraged to discuss bycannot are encouraged to discuss bybe treatment with Neupro preferablbe treatment with Neupro preferabl
Experimental group will start treatment with Neupro on Day be Experimental group will start treatment with Neupro on Dayused period, subjects randomized to the Experimental Group will use the Kinesia
used period, subjects randomized to the Experimental Group will use the Kinesia
their motor syused their motor sy mptoms (on Dayused mptoms (on Day their motor sy mptoms (on Day their motor syused their motor sy mptoms (on Day their motor sy
treatment with Neupro preferabl used treatment with Neupro preferablto randomized to the Experimental Group only
to randomized to the Experimental Group only
period, subjects randomized to the Experimental Group will use the Kinesia to period, subjects randomized to the Experimental Group will use the Kinesiasupport clinic Screening activities, assessments (including recording of Baseline 
support clinic Screening activities, assessments (including recording of Baseline 
mptoms via Kinesia
support mptoms via Kinesia -One), and training in the use of Kinesia-360 devices (for subjects 
support -One), and training in the use of Kinesia-360 devices (for subjects 
randomized to the Experimental Group only support randomized to the Experimental Group onlyany and is in line with the approved dosing regimen for rotigotine in the treatment of Parkinson’s 
any and is in line with the approved dosing regimen for rotigotine in the treatment of Parkinson’s 
disease (ie, up to 8mg/24h, depending on the stage of the disease).any disease (ie, up to 8mg/24h, depending on the stage of the disease).
clinic Screening activities, assessments (including recording of Baseline any clinic Screening activities, assessments (including recording of Baseline marketing assessment either via standard care alone (Control Group) or via a combination of standard care 
marketing assessment either via standard care alone (Control Group) or via a combination of standard care 
and evaluation of the recordings made available by
marketing and evaluation of the recordings made available by
(Experimental Group). The Neupro dosing regimen used in PD0049 follows standard of care, 
marketing (Experimental Group). The Neupro dosing regimen used in PD0049 follows standard of care, 
and is in line with the approved dosing regimen for rotigotine in the treatment of Parkinson’s marketing and is in line with the approved dosing regimen for rotigotine in the treatment of Parkinson’s 
disease (ie, up to 8mg/24h, depending on the stage of the disease).marketing disease (ie, up to 8mg/24h, depending on the stage of the disease).authorization randomized to the Control Group, subjects randomized to the Experimental Group will also use 
authorization randomized to the Control Group, subjects randomized to the Experimental Group will also use 
recording of their motor s
authorization recording of their motor s
All subjects will start Neupro treatment at a dose of either rotigotine 2mg/24h or 4mg/24h 
authorization All subjects will start Neupro treatment at a dose of either rotigotine 2mg/24h or 4mg/24h 
f the subject), which will then be adjusted based on sauthorization f the subject), which will then be adjusted based on s
assessment either via standard care alone (Control Group) or via a combination of standard care authorization assessment either via standard care alone (Control Group) or via a combination of standard care application 360) will be employ
application 360) will be employ
 40 subjects with Parkins
application  40 subjects with Parkins on’s disease of an
application on’s disease of an
be randomized (1:1 ratio) to either the Control Group or the Experimental Group. Specific motor 
application be randomized (1:1 ratio) to either the Control Group or the Experimental Group. Specific motor 
ONE on Dayapplication ONE on Day
randomized to the Control Group, subjects randomized to the Experimental Group will also use application randomized to the Control Group, subjects randomized to the Experimental Group will also use and subjects’ Neupro dosing regimens and ensure better patient outcomes in a timelier manner.
and subjects’ Neupro dosing regimens and ensure better patient outcomes in a timelier manner.
360) will be employ and 360) will be employany mptoms in subjects with Parkinson’s disease aiming at enabling Investigators
any mptoms in subjects with Parkinson’s disease aiming at enabling Investigators
subjects’ Neupro dosing regimens and ensure better patient outcomes in a timelier manner. any subjects’ Neupro dosing regimens and ensure better patient outcomes in a timelier manner.extensions mptoms in subjects with Parkinso
extensions mptoms in subjects with Parkinso
y using wearable devices. 
extensions y using wearable devices. 
y, this study focuses on investigating how to optimize the evaluation of motor extensions y, this study focuses on investigating how to optimize the evaluation of motor 
mptoms in subjects with Parkinson’s disease aiming at enabling Investigatorsextensions mptoms in subjects with Parkinson’s disease aiming at enabling Investigatorsor variations CH) 
variations CH) thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 8of 39Evaluate whether Parkinson’s disease motor s ymptoms in subjects starting Neupro can be 
improved by  using feedback of motor s ymptom data from the Kinesia-360 wearable 
technology  presented to subjects and Investigators in addition to standard clinical practice as 
compared with only standard clinical practice.
Evaluate the Neupro dosing regimen when using feedback of motor s ymptom data c ollected 
with the Kinesia- 360 wearable technology  in addition to standard clinical practice as 
compared with only standard clinical practice.
Evaluate whether subjects with Parkinson’s disease are more likel y to continue the usage of 
Neupro if Parkinson’s disease motor s ymptom data collected using the Kinesia-360 wearable 
technology  is used to provide the subjects with feedback on the status of their Parkinson’s 
disease motor s ymptoms and is used in addition to standard of care for titrating their Neupro 
dosing regimen.
2.1.2 Other objectives
Other objectives of this study are to:
Evaluate whether the quality  of life of subjects with Parkinson’s disease can be improved by 
using the Kinesia -360 wearable technology  to collect motor sy mptom data in addition to 
standa rd clinical practice as compared with only  standard clinical practice to titrate the 
Neupro dosing regimen.
Evaluate whether subjects with Parkinson’s disease are more actively engaged in the 
management and treatment of their disease with Neupro therap y with the use of the 
Kinesia- 360 wearable technology  as compared to without the use of the Kinesia-360 
wearable technology.
Evaluate the safet y of Neupro.
2.2 Stud y variables
2.2.1 Efficacy  variable s
2.2.1.1 Primary  efficacy  variable s
The primary  efficacy  variables of this study  are:
Change from Baseline (Visit 1/Week 1) to Visit 2 (Week 12/3 months after start of treatment 
with Neupro) in Unified Parkinson’s Disease Rating Scale (UPDRS) Part III Motor Score 
Change from Baseline (Visit 1/Week 1) to Visit 2 (Week 12) in Kine sia-ONE variables:
finger tapping speed score
rest tremor score
averaged finger tapping speed and resting tremor scores
postural tremor score
finger tapping amplitude score
hand grasp speed scoreREDACTED Evaluate whether subjects with Parkinson’s disease are more actively engaged in the 
REDACTED Evaluate whether subjects with Parkinson’s disease are more actively engaged in the 
management and treatment of their disease with Neupro therap
REDACTED management and treatment of their disease with Neupro therap
 as compared to without the use of the Kinesia
REDACTED  as compared to without the use of the KinesiaCOPY  standard clinical practice to titrate the 
COPY  standard clinical practice to titrate the 
Evaluate whether subjects with Parkinson’s disease are more actively engaged in the COPY Evaluate whether subjects with Parkinson’s disease are more actively engaged in the 
This document cannot finger tapping speed score
cannot finger tapping speed score
cannot be Change from Baseline (Visitbe Change from Baseline (Visitused Change from Baseline (Visit
used Change from Baseline (Visit
with Neupro) in Unified Parkinson’s Disease Rating Scale (UPDRS) Part
used with Neupro) in Unified Parkinson’s Disease Rating Scale (UPDRS) Part
Change from Baseline (Visitused Change from Baseline (Visitto Change from Baseline (Visit to Change from Baseline (Visitsupport  efficacy
support  efficacy
 variables of this support  variables of this 
Change from Baseline (Visitsupport 
Change from Baseline (Visitany ariable
any ariable s
any s
 efficacyany  efficacymarketing variables
marketing variables
smarketing sauthorization Evaluate whether subjects with Parkinson’s disease are more actively engaged in the 
authorization Evaluate whether subjects with Parkinson’s disease are more actively engaged in the 
management and treatment of their disease with Neupro therap
authorization management and treatment of their disease with Neupro therap
 as compared to without the use of the Kinesia
authorization  as compared to without the use of the Kinesiaapplication  of life of subjects with Parkinson’s disease can be improved by
application  of life of subjects with Parkinson’s disease can be improved by
 to collect motor sy
application  to collect motor sy mptom data in addition to 
application mptom data in addition to  to collect motor sy mptom data in addition to  to collect motor sy
application  to collect motor sy mptom data in addition to  to collect motor sy
 standard clinical practice to titrate the 
application  standard clinical practice to titrate the and  of life of subjects with Parkinson’s disease can be improved byand  of life of subjects with Parkinson’s disease can be improved byany extensions 360 wearable 
extensions 360 wearable 
 is used to provide the subjects with feedback on the status of their Parkinson’s 
extensions  is used to provide the subjects with feedback on the status of their Parkinson’s 
ptoms and is used in addition to standard of care for titrating their Neupro 
extensions ptoms and is used in addition to standard of care for titrating their Neupro or y to continue the usage of 
or y to continue the usage of 
360 wearable or 360 wearable variations y to continue the usage of variations y to continue the usage of thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 9of 39hand grasp amplitude score
rapid alternating movement speed score
rapid alternating amplitude score
dyskinesia score
kinetic tremor score
rapid alternating movement rhy thm score
hand movements rh ythm score
finger tapping rh ythm score
average Kinesia- ONE score
Neupro dose per 24h at Visit 2 (Week 12) 
Number of Neupro dose changes during the stud y (between Visit 1 and Visit 2) 
Discontinuation of treatment with Neupro during the course of the study
2.2.1.2 Other efficacy  variable s
Other efficacy  varibles are:
Change from Baseline to Visit 2 in the motor scores derived from t he Kinesia -360 wearable 
technology  by time (weekly /monthly ) for the Experimental Group in:
average daily tremor score
average daily slowness score
average dail y dyskinesia score
percent wear-time tremor detected
percent wear- time dy skinesia detected
percent wear- time user not moving
percent wear-time user was walking score
percent wear-time user active but not walking
number of steps per hour while wearing device
Number of day s on Kinesia -360 device
Change from Baseline to Visit 2 (Week 12) in the 39- Item Parkinson’s Disease 
Questionnaire (PDQ -39) scores.
Change from Baseline to Visit 2 (Week 12) in subject engagement questionnaire scores.
2.2.2 Safety  variable
Safety variable is:
Occurrence of AEs REDACTED 2 in the motor scores derived from t
REDACTED 2 in the motor scores derived from t
) for the Experimental Group in:
REDACTED ) for the Experimental Group in:
y slowness scoreREDACTED y slowness scoreCOPY 2 in the motor scores derived from t COPY 2 in the motor scores derived from t
This document Change from Baseline to Visit
document Change from Baseline to Visit
Questionnaire (PDQ
document Questionnaire (PDQcannot Number of day
cannot Number of day
cannot Change from Baseline to Visitcannot Change from Baseline to Visitbe number of steps per hour while wearing devicebe number of steps per hour while wearing deviceused percent wear
used percent wear
number of steps per hour while wearing deviceused number of steps per hour while wearing deviceto percent wearto percent wear -to -time user was walking scoreto time user was walking scoresupport time dy
support time dy skinesia detected
support skinesia detected
time user not moving
support time user not moving
time user was walking scoresupport time user was walking scoreany time tremor detected
any time tremor detected
skinesia detectedany skinesia detectedmarketing kinesia score
marketing kinesia score
time tremor detected marketing time tremor detectedauthorization 2 in the motor scores derived from t
authorization 2 in the motor scores derived from t
) for the Experimental Group in:
authorization ) for the Experimental Group in:application Discontinuation of treatment with Neupro during the course of the study
application Discontinuation of treatment with Neupro during the course of the studyand (between Visit 1 and Visit
and (between Visit 1 and Visit
Discontinuation of treatment with Neupro during the course of the studyand Discontinuation of treatment with Neupro during the course of the studyany (between Visit 1 and Visitany (between Visit 1 and Visitextensions or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 10of 392.3 Stud y design and conduct
PD0049 is a multicenter, open-label, two- arm, 12- week stud y in subjects with Parkinson’s 
disease. On Day 1, eligible subjects will be randomized to either the Control Group or the 
Experimental Group in a 1:1 fashion. In both groups, subjects will use the Kinesia- ONE 
wearable devic e in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms, and 
subjects randomized to the Experimental Group will also use the Kinesia-360 wearable device at 
home while awake for continuous measurement of motor symptoms. The Investigator will use these sy mptom data to provide feedback to subjects on their motor sy mptoms and to supplement 
standard of care to titrate the optimal dose of Neupro for an y given subject. I n the Control 
Group, subjects will not use any wearable device at home, and the Investigator will use only  
standard of care to titrate the optimal Neupro dose.
Subjects in the Control Group and the Experimental Group will start treatment with Neupro 
2mg/24h or 4mg/24h (at the Investigator’s discretion and according to the disease stage of the subject) preferably  on Day 1 (but no later than Day  4) or Day 4, respectively . Evaluations 
conclude 12 weeks after the start of treatment with Neupro (ie, at Visit 2).
The Neupro dosing regimen used in PD0049 follows standard of care, and is in line with the approved dosing regimen for rotigotine in the treatment of Parkinson’s disease (ie, up to 
8mg/24h, depending on the stage of the disease).
The decision to prescribe Neupro must be made by the Investigator independent of his/her 
decision to include the subject in the study . The subject’s treatment/Neupro intake must be 
within the terms of the marketing authorization; Neupro will not be supplied by UCB.
Each subject’s participation is approximately  12 weeks. The end of the study  is defined as the 
date of the last visit of the last subject in the study.
This stud y will be conducted in the US, in approximately  6 sites and will include a total of 
approximately  40 subjects (20 subjects in the Experimental Group and 20 subjects in the Control 
Group). Of note, a single site will not randomize more than 20 subjects.A schedule of stud y assessments is presented in Table 2‒1 :
Table 2‒1: Schedule of study assessments
In Clinic At Home In Clinic
SCREENING BASELINE EOS/EW
Visit 1 Visit 2
Assessments Day 1 Day 
2-3Day 
4Week 
2Week 
3Week 
4Week 
11Week 12
(±3 days)
Written informed consent X
Demographic data 
(incl. height and weight)X Xa
Kinesia- ONE subject 
assessments (measured in 
triplicate)XbXREDACTED . The subject’s treatment/Neupro intake must be 
REDACTED . The subject’s treatment/Neupro intake must be 
within the terms of the marketing authorization; Neupro will not be supplied by UCB.
REDACTED within the terms of the marketing authorization; Neupro will not be supplied by UCB.
Each subject’s participation is approximately
REDACTED Each subject’s participation is approximately
date of the last visit of the last subject in the study.REDACTED date of the last visit of the last subject in the study.COPY The decision to prescribe Neupro must be made by the Investigator independent of his/her 
COPY The decision to prescribe Neupro must be made by the Investigator independent of his/her 
. The subject’s treatment/Neupro intake must be COPY . The subject’s treatment/Neupro intake must be 
This document Written informed consent
document Written informed consent
document document document document document document cannot Assessments
cannot Assessments
cannot be used to to support ssessments is presented in 
support ssessments is presented in 
Schedule of study
support Schedule of study
support any ). Of note, a single site will not randomize more than 20 subjects.
any ). Of note, a single site will not randomize more than 20 subjects.
ssessments is presented in any ssessments is presented in marketing date of the last visit of the last subject in the study.
marketing date of the last visit of the last subject in the study.
y will be conducted in the US, 
marketing y will be conducted in the US, in approximately
marketing in approximately
subjects in the Experimental Group and 20
marketing subjects in the Experimental Group and 20
). Of note, a single site will not randomize more than 20 subjects. marketing ). Of note, a single site will not randomize more than 20 subjects.authorization The decision to prescribe Neupro must be made by the Investigator independent of his/her 
authorization The decision to prescribe Neupro must be made by the Investigator independent of his/her 
. The subject’s treatment/Neupro intake must be 
authorization . The subject’s treatment/Neupro intake must be 
within the terms of the marketing authorization; Neupro will not be supplied by UCB.
authorization within the terms of the marketing authorization; Neupro will not be supplied by UCB.
Each subject’s participation is approximately
authorization Each subject’s participation is approximately  12
authorization  12 Each subject’s participation is approximately  12 Each subject’s participation is approximately
authorization Each subject’s participation is approximately  12 Each subject’s participation is approximately weeks. The end of the study
authorization weeks. The end of the study
date of the last visit of the last subject in the study. authorization date of the last visit of the last subject in the study.application The Neupro dosing regimen used in PD0049 follows standard of care, and is 
application The Neupro dosing regimen used in PD0049 follows standard of care, and is 
approved dosing regimen for rotigotine in the treatment of Parkinson’s disease (ie, up to 
application approved dosing regimen for rotigotine in the treatment of Parkinson’s disease (ie, up to 
The decision to prescribe Neupro must be made by the Investigator independent of his/her application The decision to prescribe Neupro must be made by the Investigator independent of his/her and 4, respectively
and 4, respectively
weeks after the start of treatment with Neupro (ie, at Visit
and weeks after the start of treatment with Neupro (ie, at Visit 2).
and 2).
The Neupro dosing regimen used in PD0049 follows standard of care, and is and The Neupro dosing regimen used in PD0049 follows standard of care, and is any nvestigator’s discretion and according to the disease
any nvestigator’s discretion and according to the disease
4, respectivelyany 4, respectively . Evaluations any . Evaluations extensions the Investigator will use only
extensions the Investigator will use only
Subjects in the Control Group and the Experimental Group will start treatment with Neupro 
extensions Subjects in the Control Group and the Experimental Group will start treatment with Neupro 
nvestigator’s discretion and according to the disease extensions nvestigator’s discretion and according to the diseaseor n the Control or n the Control 
the Investigator will use onlyor the Investigator will use onlyvariations will use 
variations will use 
mptoms and to supplement variations mptoms and to supplement thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 11of 39Table 2‒1: Schedule of study assessments
In Clinic At Home In Clinic
SCREENING BASELINE EOS/EW
Visit 1 Visit 2
Assessments Day 1 Day 
2-3Day 
4Week 
2Week 
3Week 
4Week 
11Week 12
(±3 days)
UPDRS X X
Patient engagement 
questionnaireX X
PDQ -39 X X
Verification of 
inclusion/exclusion criteriaX
Randomization X
C Group: Start treatment 
with Neupro 2mg or 4mg 
preferably on Day 1 but no 
later than Day 4 (dose 
adjustments during study 
are performed per standard 
of care) X X
C Group: Record Neupro dose X X
E Group: Kinesia -360 
device training and 
distribution of equipmentX
E Group: Subject wears 
Kinesia-360 wrist and 
ankle devices on Days 2 and 3 at home for baselineX
E Group: Start treatment 
with Neupro 2mg or 4mg on Day 4X
E Group: Record Neupro 
dosecX X
E Group: Reminder 
phone calls from site to subject at beginning of Weeks 2, 3, 4 and 11 
(remind subject to charge 
devices and wear devices 
on at least 2 consecutive XdXdXdXdREDACTED X
REDACTED X
REDACTED COPY COPY 
This document ose
document ose
E Group: 
document E Group: 
phone calls from site to 
document phone calls from site to 
document document document cannot E Group: 
cannot E Group: 
osecannot oseccannot ccannot be with Neupro 2mg or 4mg be with Neupro 2mg or 4mg used and 3 at home for baseline
used and 3 at home for baseline
Start treatment used Start treatment 
with Neupro 2mg or 4mg used with Neupro 2mg or 4mg used to ankle devices on Days 2 
to ankle devices on Days 2 
and 3 at home for baseline to and 3 at home for baselinesupport ankle devices on Days 2 support ankle devices on Days 2 
and 3 at home for baselinesupport 
and 3 at home for baselinesupport support any any marketing marketing marketing marketing marketing authorization authorization authorization application application application and and and and and and any any extensions extensions extensions extensions extensions extensions extensions extensions extensions extensions or variations variations Week 12
variations Week 12
(±3 days)
variations (±3 days)
variations variations variations variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 12of 39Table 2‒1: Schedule of study assessments
In Clinic At Home In Clinic
SCREENING BASELINE EOS/EW
Visit 1 Visit 2
Assessments Day 1 Day 
2-3Day 
4Week 
2Week 
3Week 
4Week 
11Week 12
(±3 days)
days during Weeks 2, 3, 4 
and 11)
E Group: Subject wears 
Kinesia-360 wrist and 
ankle devices on at least 2 
consecutive days at homeXXXX
E Group: Subject and 
Investigator access 
Kinesia-360 device reports 
(subjects via device app, 
Investigators via GLNT 
web portal)X X
E Group: Investig ator
combines st andard of care
withKines ia-360 motor 
symptom reports toadjust
Neupro dose andis
encour agedtocontactthe
subjectby phone to 
discuss motor symptom reports and potential 
Neupro d oseadjustm ents
anytimebetween V1and
V2based on clinical 
judgment X
E Group: Subject returns 
Kinesia-360 device 
equipment to siteX
Record adverse events X X
Record concomitant 
medicationsX X
APP=application; C Group=Contr olGroup; E Group=Experi mental Grou p; EOS=End of Study; EW=Early 
Withdraw al; GLNT=Great Lakes Neuro Technologies, Inc.; P DQ-39=39 -Item Parkinson’s disease questio nnaire; 
UPDRS =Unif iedParkinson’s Di seaseRating Scal e; V=visit
aOnly weight at V2.
bThe average of the triplicate resting tremor scores and triplicate finger tapping scores from Kinesia -ONE must be 
>1.0 to be eligible for inclusion in this study.REDACTED REDACTED COPY COPY 
This document medications
document medications
document APP=application; C
document APP=application; Ccannot Record adverse events
cannot Record adverse events
cannot cannot Record concomitant cannot Record concomitant 
medicationscannot medicationscannot be equipment to sitebe equipment to sitebe used Subject returns 
used Subject returns 
-360 device used -360 device 
equipment to siteused equipment to siteto Subject returns to Subject returns to support support any marketing marketing authorization authorization application and any any extensions extensions XXXX
extensions XXXX
extensions extensions extensions extensions extensions or variations variations Week 12
variations Week 12
(±3 days)
variations (±3 days)
variations variations variations variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 13of 39cSubjects in the Experimental Group will be prompted to record Neupro dose in device app during each use of 
Kinesia -360 betw een V1 and V2.
dSubjects in the Experimental Group are to use Kinesia -360 on at least 2 consecutive days during Weeks 2, 3, 4 and 
11, but are free to use the device as often as they like between these time points prior to Visit 2.
2.4 Determination of sample size
Due to the character of the study , no formal sample size estimation can be performed. A sample 
size of approximately  40 will be regarded to be sufficient to get an impression of the effect of the 
device on the efficacy  variables.
3 DATA  ANALYSIS CONSID ERA TIONS
3.1 General presentation of summaries and analy ses
The statistical anal yses will be performed by Chiltern. Computations and generation of outputs 
will be performed using SAS® (Statistical Analy sis Sy stem, SAS- Institute, Cary, NC, USA) 
Version 9.3 or above. All tables and listings will use Courier New font size 9.
For continuous data in general, summary statistics (n [number of available measurements], 
arithmetic mean, standard deviation (SD), median, minimum, and maximum) will be presented 
by group. For selected variables, the first (25th percent) quartile (Q1) and the third (75th percent) 
quartile (Q3) may also be presented (for patient reported outcomes).
Mean, SD, median and quartiles will be displayed to 1 more decimal place than collected in the 
source data. Derived variables in general will display  the mean, SD and median to 1 more 
decimal place than the variables used in the derivation (i.e. a change from Baseline will be 
reported to the same precision as the Baseline data). However, a special rule can be defined as 
needed for appropriate reporting.
For descriptive statistics of continuous variables by visit, the change from Baseline and actual 
value at the given time point will be displayed. The change from Baseline is the post- Baseline 
value minus the Baseline value. If the Baseline or post-Baseline value is missing, then the 
change from Baseline is set to missing. Percent change from Baseline is the change from 
Baseline divided b y Baseline and multiplied by  100. If the Baseline value is 0 and the post-
Baseline value is also 0, then the percent change from Baseline is set to 0. If the Baseline value is 
0 and the post-Baseline value is non-zero, then the percent change from Baseline is set to 
missing. If the Baseline value is missing, the percent change from Baseline is set to mis sing.
Frequency tables (frequency  counts and percentages) will be presented for categorical data. If 
there are no missing values then the missing row can be removed. If there are missing values (including missing a single assessment or entire visit), then include the missing row with the 
frequency  count and percentage. If there are no subjects in a specific CRF category , then that 
row will be retained and 0 presented in the table. In general, percentages will be calculated based 
on the utilized analy sis set. However, in the case of subgroup anal yses, the N of the subgroup 
will be used as denominator.
Unless stated otherwise, all inferential statistical tests will be 2-sided and conducted at the 0.05 
alpha level. P-values will be presented to 3 decimal places. 
All data in the database (ADaM) will be presented in by- subject data listings, and sorted by  
group, site, subject number, variable (where applicable), and visit (where applicable). All listings REDACTED general will display
REDACTED general will display
decimal place than the variables used in the derivation (i.e. a change from Baseline will be 
REDACTED decimal place than the variables used in the derivation (i.e. a change from Baseline will be 
reported to the same precision as the Baseline data). However, a special rule can be defined as 
REDACTED reported to the same precision as the Baseline data). However, a special rule can be defined as 
For descriptive statistics of continuous variables by visit, the change from Baseline and actual REDACTED For descriptive statistics of continuous variables by visit, the change from Baseline and actual COPY  also be presented (for patient reported outcomes).
COPY  also be presented (for patient reported outcomes).
ed to 1 more decimal place than collected in the 
COPY ed to 1 more decimal place than collected in the 
general will display COPY general will display
This document row will be retained and 0 presented in the table. In general, percentages will be calculated based 
document row will be retained and 0 presented in the table. In general, percentages will be calculated based 
document on the utilized analy
document on the utilized analy
will be used as denominator.
document will be used as denominator.cannot (including missing a single assessment or entire visit), then 
cannot (including missing a single assessment or entire visit), then 
frequency
cannot frequency  count and percentage. If there are no subjects in a specific CRF category
cannot  count and percentage. If there are no subjects in a specific CRF category frequency  count and percentage. If there are no subjects in a specific CRF category frequency
cannot frequency  count and percentage. If there are no subjects in a specific CRF category frequency
row will be retained and 0 presented in the table. In general, percentages will be calculated based cannot row will be retained and 0 presented in the table. In general, percentages will be calculated based be there are no missing values then the missing row can be removed. If there are missing values 
be there are no missing values then the missing row can be removed. If there are missing values 
(including missing a single assessment or entire visit), then be (including missing a single assessment or entire visit), then used missing. If the Baseline value is missing, the percent change from Baseline is set to mis
used missing. If the Baseline value is missing, the percent change from Baseline is set to mis
 tables (frequency
used  tables (frequency
there are no missing values then the missing row can be removed. If there are missing values used there are no missing values then the missing row can be removed. If there are missing values to missing. If the Baseline value is missing, the percent change from Baseline is set to misto missing. If the Baseline value is missing, the percent change from Baseline is set to missupport Baseline and multiplied by
support Baseline and multiplied by
then the percent change from Baseline is set to 0. If the Baseline value is 
support then the percent change from Baseline is set to 0. If the Baseline value is 
Baseline value is nonsupport Baseline value is non
missing. If the Baseline value is missing, the percent change from Baseline is set to missupport missing. If the Baseline value is missing, the percent change from Baseline is set to misany change from Baseline is set to missing. Percent change from Baseline is the change from 
any change from Baseline is set to missing. Percent change from Baseline is the change from 
Baseline and multiplied by any Baseline and multiplied bymarketing For descriptive statistics of continuous variables by visit, the change from Baseline and actual 
marketing For descriptive statistics of continuous variables by visit, the change from Baseline and actual 
value at the given time point will be display
marketing value at the given time point will be display
value minus the Baseline value. If the Basmarketing value minus the Baseline value. If the Bas
change from Baseline is set to missing. Percent change from Baseline is the change from marketing change from Baseline is set to missing. Percent change from Baseline is the change from authorization ed to 1 more decimal place than collected in the 
authorization ed to 1 more decimal place than collected in the 
general will display
authorization general will display  the mean, SD and median to 1 more 
authorization  the mean, SD and median to 1 more general will display  the mean, SD and median to 1 more general will display
authorization general will display  the mean, SD and median to 1 more general will display
decimal place than the variables used in the derivation (i.e. a change from Baseline will be 
authorization decimal place than the variables used in the derivation (i.e. a change from Baseline will be 
reported to the same precision as the Baseline data). However, a special rule can be defined as 
authorization reported to the same precision as the Baseline data). However, a special rule can be defined as application  statistics (n [number of available measurements], 
application  statistics (n [number of available measurements], 
arithmetic mean, standard deviation (SD), median, minimum, and maximum)
application arithmetic mean, standard deviation (SD), median, minimum, and maximum)
(25th percent) quartile (Q1) and the third (75th percent) 
application (25th percent) quartile (Q1) and the third (75th percent) 
 also be presented (for patient reported outcomes).
application  also be presented (for patient reported outcomes).
ed to 1 more decimal place than collected in the application ed to 1 more decimal place than collected in the and  statistics (n [number of available measurements], and  statistics (n [number of available measurements], 
arithmetic mean, standard deviation (SD), median, minimum, and maximum)and arithmetic mean, standard deviation (SD), median, minimum, and maximum)any Institute, Cary
any Institute, Cary
l use Courier New font size 9.any l use Courier New font size 9.extensions y Chiltern. Computations and generation of outputs 
extensions y Chiltern. Computations and generation of outputs 
Institute, Cary extensions Institute, Caryor variations  40 will be regarded to be sufficient to get an impression of the effect of the 
variations  40 will be regarded to be sufficient to get an impression of the effect of the thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 14of 39will include repeated and unscheduled measurements. Such measurements will appear in 
chronological order. In all the listings dates will be presented in the format ‘YYYY- MM- DD’ 
and times will be presented in 24h clock format as ‘hh:mm’. The visit dates and phone contact dates will be presented in a listing. This includes the scheduled phone contacts in the Experimental Group and the unscheduled phone contacts in both groups. As scheduled phone 
contacts in the Experimental Group were consistently reported on both the form for scheduled 
contacts as well as on the unscheduled telephone log, duplicate phone contacts will be removed at the SDTM level. It will be considered at the SDTM level that the scheduled phone contacts do 
not appear twice, unless two or more phone contacts were documented as conducted on the same
day.
All tabulations will be sorted by variable and visit. Only  scheduled visits will be included in the 
tabulation. Categorical data will be summarized by visit, using the number and percentage of subjects in each category. Percentages will be based on the corresponding population size (i.e., the denominator of percentages should match the sample size in the column header), unless 
otherwise noted via footnote in the applicable summary table. Percentages will be presented to 1 
decimal place. For data points with n=0 (i.e., no subjects in the applicable category), no value for percentage of subjects will be display ed.
3.2 General study level definitions
3.2.1 Analysis time points
3.2.1.1 Relative Day
The relative day  of a visit or an event with respect to the first a dministratio nof study medication
(i.e. first patch application of Neupro ) will be presented in subject data listings. Relative day s 
will be calculated as follows:
If the start (stop) date occurred prior to the first application of study medication, the relative 
day is calculated as start (stop) date minus date of first patch application. That means that in 
subject data listings, relative days based on this situation will be preceded by  a ‘-‘.
If the start (stop) date occurred on or after the first application of study medication but prior 
to the last patch application, the relative day  is calculated as start (stop) date minus date of 
first patch application + 1.
If the start (stop) date occurred after the date of last patch application , the relative day is 
calculated as start (stop) date minus date of last patch application + 1. In subject data listings, relative day s based on this situation will be preceded by  a ‘+’.
Relative day s will not be presented for partial or missing dates.
3.2.1.2 End date of the Treatment Period
The end date of the Treatment P eriod will be either the date of Visit 2 for subjects completing the 
Treatment Period, or the date of the Early Withdrawal for subjects who discontinued during the 
Treatment Period. If a subject does not have a Visit 2/EW, then the date of last known dose of 
study  medication during the Treatment Period will define the end date of the Treatment Period.
3.2.2 Study periods
The following stud y periods are defined for the classification by  study  period:REDACTED  of a visit or an event with respect to the first a
REDACTED  of a visit or an event with respect to the first a
will be presented in subject data listings. Relative day
REDACTED will be presented in subject data listings. Relative dayCOPY 
This document The 
document The 
Treatment Period, or the date of the Earl
document Treatment Period, or the date of the Earlcannot Relative day
cannot Relative day
cannot 3.2.1.2cannot 3.2.1.2be relative day
be relative day
Relative daybe Relative dayused If the start (stop) date occurred afte
used If the start (stop) date occurred afte
calculated a
used calculated a s start (stop) date minus date of last patch application + 1. In subject data listings, 
used s start (stop) date minus date of last patch application + 1. In subject data listings, 
relative day used relative day s based on this situation will be preceded byused s based on this situation will be preceded byto If the start (stop) date occurred afte to If the start (stop) date occurred aftesupport If the start (stop) date occurred on or after the first application of study
support If the start (stop) date occurred on or after the first application of study
support application
support application
first patch application + 1.support first patch application + 1.any subject data listings, relative day
any subject data listings, relative day
If the start (stop) date occurred on or after the first application of study any If the start (stop) date occurred on or after the first application of studymarketing If the start (stop) date occurred prior to the first application of study
marketing If the start (stop) date occurred prior to the first application of study
 is calculated as start (stop) date minus date of first patch application. That means that in 
marketing  is calculated as start (stop) date minus date of first patch application. That means that in 
subject data listings, relative day marketing subject data listings, relative day s based on this situation will be preceded bymarketing s based on this situation will be preceded byauthorization  of a visit or an event with respect to the first a
authorization  of a visit or an event with respect to the first a
will be presented in subject data listings. Relative day
authorization will be presented in subject data listings. Relative dayapplication decimal place. For data points with n=0 (i.e., no subjects in the applicable category
application decimal place. For data points with n=0 (i.e., no subjects in the applicable categoryand  table. Percentages will be presented to 1 
and  table. Percentages will be presented to 1 
decimal place. For data points with n=0 (i.e., no subjects in the applicable categoryand decimal place. For data points with n=0 (i.e., no subjects in the applicable categoryany the denominator of percentages should match the sample size in the column header), unless 
any the denominator of percentages should match the sample size in the column header), unless 
 table. Percentages will be presented to 1 any  table. Percentages will be presented to 1 extensions  scheduled visits will be included in the 
extensions  scheduled visits will be included in the 
tabulation. Categorical data will be summarized by visit, using the number and percentage of 
extensions tabulation. Categorical data will be summarized by visit, using the number and percentage of 
corresponding population size (i.e., extensions corresponding population size (i.e., 
the denominator of percentages should match the sample size in the column header), unless extensions the denominator of percentages should match the sample size in the column header), unless or variations cheduled telephone log, duplicate phone contacts will be removed 
variations cheduled telephone log, duplicate phone contacts will be removed 
at the SDTM level. It will be considered at the SDTM level that the scheduled phone contacts do 
variations at the SDTM level. It will be considered at the SDTM level that the scheduled phone contacts do 
were documented as conducted on the same variations were documented as conducted on the samethereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 15of 39Pretreatment Period: Prior to the date of first administration of study  medication
Treatment Period: On or after the date of first administration of study medication and prior to 
or on the date of last administration of study medication during the Treatment Period.
3.2.3 Mapping of assessments perf ormed at Early  Withdrawal Visit
Efficacy  and safet y assessments at an Earl y Withdrawal Visit that correspond to a scheduled visit 
(Visit 2) will be summarized at the scheduled visit (Visit 2) if the assessment was scheduled to 
occur at that visit.
3.2.4 Rescreening
Rescreening was not foreseen in the clinical stud y protocol. However one subject was 
rescreened. In this case, the initial screening is documented with a different subject number than 
the second screening and following visits of this same subject. The fact that a rescreened subject 
has 2 different subject numbers is not accounted for in the anal ysis, which means that the subject 
willbe counted twice in the tables based on the Enrolled Set. This was decided to be acceptable 
due to the exploratory nature of this study , and will not impact the efficacy  and safet y analysis.
3.3 Definition of Baseline values
Baseline values for efficacy  and safet y variables will be determined from the last available value 
on or before the day of the first patch application, unless otherwise noted for a specific ty pe of 
data. In general, Baseline values will be the values collected at Visit 1.
3.4 Protocol deviations
Important protocol deviations are deviations from the protocol which potentially could have a meaningful impact on study  conduct or on the primary  efficacy  outcomes for an individual 
subject. The criteria for identifying important protocol deviations will be defined within the appropriate protocol-specific document. Important protocol deviations will be reviewed as part of the ongoing data cleaning process and data evaluation. All important deviations will be 
identified and documented prior to database lock to confirm exclusion from anal ysis sets.
3.5 Analysis sets
Four anal ysis sets will be defined for this study :the Enrolled Set (ES), the Safety Set (SS), the 
Full Anal ysis Set (FAS), and the Per- Protocol Set (PPS).
3.5.1 Enrolled S et
The ES will consist of all subjects who signed the Informed Consent form (ICF).
3.5.2 Safety  Set
The SS will consist of all subjects who received at least 1 dose of Neupro. A subject who received Neupro after screen failing is not considered as treated within the study  and therefore 
not included in the SS. The SS will be used for the anal ysis of all demographic, disposition, and 
safet y data.
3.5.3 Full Analysis S et
The FAS will consist of all subjects who have at least 1 valid Baseline and at least 1 valid post 
Baseline efficacy measurement. That means, subjects in FAS have non- missing values at Visit 1 REDACTED Important protocol deviations are deviations from the protocol which potentially
REDACTED Important protocol deviations are deviations from the protocol which potentially
or on the primary
REDACTED or on the primary
subject. The criteria for identifying important protocol deviations will be defined within the REDACTED subject. The criteria for identifying important protocol deviations will be defined within the COPY y variables will be determined from the last available value 
COPY y variables will be determined from the last available value 
on, unless otherwise noted for a specific ty
COPY on, unless otherwise noted for a specific ty
data. In general, Baseline values will be the values collected at Visit 1.COPY data. In general, Baseline values will be the values collected at Visit 1.
This document The SS will consist of all subjects who received at least 1 dose of Neupro. 
document The SS will consist of all subjects who received at least 1 dose of Neupro. 
received Neupr
document received Neupr
not included in the SS. 
document not included in the SS. cannot The SS will consist of all subjects who received at least 1 dose of Neupro. cannot The SS will consist of all subjects who received at least 1 dose of Neupro. be The ES will consist of all subjects who signed the be The ES will consist of all subjects who signed the used Enrolled 
used Enrolled 
The ES will consist of all subjects who signed the used The ES will consist of all subjects who signed the to is Set (FAS), and the Per-to is Set (FAS), and the Per- support s
support sets
support ets
is sets will be defined for this studysupport is sets will be defined for this study
is Set (FAS), and the Per- support is Set (FAS), and the Per-any identified and documented prior to database lock to confirm exclusion from anal
any identified and documented prior to database lock to confirm exclusion from anal
etsany etsmarketing or on the primary
marketing or on the primary
subject. The criteria for identifying important protocol deviations will be defined within the 
marketing subject. The criteria for identifying important protocol deviations will be defined within the 
specific document. Important protocol deviations will be reviewed as part 
marketing specific document. Important protocol deviations will be reviewed as part 
of the ongoing data cleaning process and data emarketing of the ongoing data cleaning process and data e
identified and documented prior to database lock to confirm exclusion from analmarketing identified and documented prior to database lock to confirm exclusion from analauthorization on, unless otherwise noted for a specific ty
authorization on, unless otherwise noted for a specific ty
data. In general, Baseline values will be the values collected at Visit 1.
authorization data. In general, Baseline values will be the values collected at Visit 1.
Important protocol deviations are deviations from the protocol which potentially
authorization Important protocol deviations are deviations from the protocol which potentially
or on the primary authorization or on the primaryapplication y variables will be determined from the last available value 
application y variables will be determined from the last available value 
on, unless otherwise noted for a specific tyapplication on, unless otherwise noted for a specific ty
data. In general, Baseline values will be the values collected at Visit 1.application data. In general, Baseline values will be the values collected at Visit 1.and This was decided to be acceptable 
and This was decided to be acceptable 
, and will not impact the efficacyand , and will not impact the efficacyany is, which means that
any is, which means that
This was decided to be acceptable any This was decided to be acceptable extensions subject was 
extensions subject was 
In this case, the initial screening is documented with a different subject number than 
extensions In this case, the initial screening is documented with a different subject number than 
ct. The fact that a rescreened subject extensions ct. The fact that a rescreened subject 
is, which means that extensions is, which means thator variations y Withdrawal Visit that correspond to a scheduled visit 
variations y Withdrawal Visit that correspond to a scheduled visit 
(Visit 2) will be summarized at the scheduled visit (Visit 2) if the assessment was scheduled to 
variations (Visit 2) will be summarized at the scheduled visit (Visit 2) if the assessment was scheduled to thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 16of 39and at Visit 2 either for the UPDRS Part III Motor Score or for at least one Kinesia- ONE 
variable or for Neu pro dose per 24h.
The FAS will be used for the anal ysis and presentation of the efficacy  data. In the case of 
misallocation, subjects will primarily  be analy zed according to Kinesia- 360 application (y es/no). 
However, if applicable, sensitivity  anal ysis wil l also be performed according to the randomized 
group.
3.5.4 Per Protocol S et
The PPS will consist of those subjects in the FAS who do not have any important protocol 
deviations that would have an impact on the primary  efficacy  variables. The PPS will be used for 
sensitivity  anal ysis.
3.6 Treatment a ssignment an d treatment groups
Eligible Subjects will be randomized to either the Control Group or the Experimental Group. In 
the Control Group, optimal Neupro dosing regimen will be titrated using standard clinical 
practice only. In the Experimental Group, optimal Neupro dosing regimen will be titrated using 
motor sy mptom data collected with the Kinesia- 360 wearable technology  in addition to standard 
clinical practice.
Comparisons between Control Group and Experimental Group will be performed for outcomes 
where data are available for both groups, e.g. Kinesia-ONE data, and questionnaires. Kinesia-
360 data however areonly available for subjects in the Experimental Group, and will therefore 
be presented only  for this g roup.
3.7 Center pooling s trategy
No pooling of centers is planned for this study.
3.8 Coding dictionaries
All AEs will be coded for anal ysis according to the Medical Dictionary  for Regulatory Activities 
(MedDRA)®coding dictionary , using the latest version available. Prior and concomitant 
medications will be coded for anal ysis using the latest version of the World Health Organization 
Drug dictionary  (WHO- DD).
3.9 Changes to protocol -defined analy ses
Additional Kinesia-ONE scores which we re not prespecified in the clinical study  protocol are 
provided by the vendor. These will be analyzed in the same way as the prespecified variables.
4 STATISTICA L/ANALYTIC AL ISSUES
4.1 Adjustments for c ovariates
The continuous efficacy variables, change from Baseline to Visit 2 (for all efficacy  variables not 
based on Kinesia- 360) will be analyzed utilizing an anal ysis of covariance (ANCOVA) with 
Baseline as a covariate, “center” as factor, and “group” as main factor. The adjustments for baseline value and center are included, as t hese variables may  have a s ystematic impact on the 
efficacy  outcome.REDACTED  available for subjects in the Experimental Group, and will therefore 
REDACTED  available for subjects in the Experimental Group, and will therefore 
trategy
REDACTED trategy
No pooling of centers is planned for this studyREDACTED No pooling of centers is planned for this studyCOPY Comparisons between Control Group and Experiment
COPY Comparisons between Control Group and Experiment al Group will be performed for outcomes 
COPY al Group will be performed for outcomes 
available for both groups, e.g. Kinesia
COPY available for both groups, e.g. Kinesia -ONE data, and questionnaires. Kinesia-
COPY -ONE data, and questionnaires. Kinesia-
 available for subjects in the Experimental Group, and will therefore COPY  available for subjects in the Experimental Group, and will therefore 
This document The continuous efficacy
document The continuous efficacy
based on Kinesia
document based on Kinesiacannot be y the vendor. These will be analyzed in the same way as 
be y the vendor. These will be analyzed in the same way as used Additional Kinesia-ONE scores which we
used Additional Kinesia-ONE scores which we
y the vendor. These will be analyzed in the same way as used y the vendor. These will be analyzed in the same way as to Changes to protocolto Changes to protocol support medications will be coded for anal
support medications will be coded for anal
DD).
support DD).
Changes to protocol support Changes to protocolany is according to the Medical Dictionary
any is according to the Medical Dictionary
any coding dictionaryany coding dictionary , using the latest version availaany , using the latest version availa
medications will be coded for analany medications will be coded for analmarketing No pooling of centers is planned for this study
marketing No pooling of centers is planned for this study
Coding dictionaries
marketing Coding dictionaries
is according to the Medical Dictionarymarketing is according to the Medical Dictionaryauthorization -ONE data, and questionnaires. Kinesia-
authorization -ONE data, and questionnaires. Kinesia-
 available for subjects in the Experimental Group, and will therefore 
authorization  available for subjects in the Experimental Group, and will therefore 
trategy
authorization trategy
No pooling of centers is planned for this studyauthorization No pooling of centers is planned for this studyapplication 360 wearable technology
application 360 wearable technology
al Group will be performed for outcomes 
application al Group will be performed for outcomes 
-ONE data, and questionnaires. Kinesia-application -ONE data, and questionnaires. Kinesia-and men will be titrated using 
and men will be titrated using 
n the Experimental Group, optimal Neupro dosing regimen will be titrated using and n the Experimental Group, optimal Neupro dosing regimen will be titrated using 
360 wearable technologyand 360 wearable technologyany Eligible Subjects will be randomized to either the Control Group or the Experimental Group. In 
any Eligible Subjects will be randomized to either the Control Group or the Experimental Group. In 
standard clinical any standard clinical extensions  variables. The PPS will be used fo
extensions  variables. The PPS will be used fo
Eligible Subjects will be randomized to either the Control Group or the Experimental Group. In extensions Eligible Subjects will be randomized to either the Control Group or the Experimental Group. In or y important protocol or y important protocol 
 variables. The PPS will be used fo or  variables. The PPS will be used fovariations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 17of 394.2 Handling of dropouts or missing data
Subjects who prematurely discontinue the study will be evaluated based on the data collected at 
the Withdrawal Visit. The Withdrawal Visit data will be used similar to Visit 2 data.
Adverse events with missing intensity will be assumed to be severe. Adverse events with missing 
relationship to study  medication per the investigator will be assumed to be related.
For analy ses of AEs and concomitant medication usage, a complete date must be established in 
order to correctly identify  the AE or medication as occurring during treatment or not. For 
purposes of imputing missing components of partially-reported start and stop dates for AEs and 
for medication use, the algorithms listed below will be followed. Start and stop dates of AEs or 
concomitant medication will be display ed as reported in the subject data listings (i.e., no imputed 
values will be displayed in data listings).
Missing start day, but month and y ear present: If the start of stud y medication occurred in the 
same month and y ear as the occurrence of the AE/concomitant medication, the start day  of 
the event/concomitant medication will be assigned to the day  of first application of study  
medication. Oth erwise the start day will be set to the 1st day  of the month.
Missing start day and month, but year present: If the start of study  medication occurred in the 
same y ear as the occurrence of the AE/concomitant medication, the start day  and month will 
be assi gned to the date of first application of study medication. Otherwise the start day  and 
month will be set to January 1st.
Missing end day, but month and year present: The end day will be set to the last day  of the 
month.
Missing end day and month, but y ear present: If the maximum of the subject’s date of study 
termination or the date equivalent to 30 days after the subject’s last application of study  
medication is the same year as the occurrence of the AE/Concomitant medication, then the 
end day  and month will be set to the maximum of the date of stud y termination or the date 
equivalent to 30 day s after last application of study medication. Otherwise the end day will 
be set to December 31st of the given year.
4.3 Interim anal yses and data m onitoring
No formal interim anal ysis is planned for PD0049. Also, no specific data monitoring, steering, or 
evaluation committee is planned for this study.
4.4 Multicenter s tudies
No multicenter anal yses are planned. Therefore, this section is not applicable for this study.
4.5 Multi ple comparisons/multiplicity
All statistical tests are considered exploratory, and calculated p-values <0.05 do not indicate 
statistical significance, since no alpha adjustment will be performed.
4.6 Use of an e fficacy  subset of subjects
The FAS will be used a s primary  anal ysis set for efficacy  anal yses. The primary  efficacy  
analyses will be repeated for the PPS. The PPS will be used to evaluate subjects who have 
efficacy  data and are reasonably compliant with the conditions of the study . This analy sis set willREDACTED ear present: The end day
REDACTED ear present: The end day
 and month, but yREDACTED  and month, but y ear REDACTED ear present: If the maximum of the subject’s date of studyREDACTED present: If the maximum of the subject’s date of study
termination or the date equivalent to 30 day REDACTED termination or the date equivalent to 30 dayCOPY ear as the occurrence of the AE/concomitant medication, the start day
COPY ear as the occurrence of the AE/concomitant medication, the start day
of study medication. Otherwise the start day
COPY of study medication. Otherwise the start day
This document All statistical tests are considered exploratory
document All statistical tests are considered exploratory
statistical significance, since no alpha adjustment will be performed.
document statistical significance, since no alpha adjustment will be performed.cannot No multicenter anal
cannot No multicenter analbe used evaluation committee is planned for this study.
used evaluation committee is planned for this study.
Multicenter sused Multicenter sto interim analto interim anal
evaluation committee is planned for this study.to evaluation committee is planned for this study.support be set to December 31st of the given 
support be set to December 31st of the given 
Interim 
support Interim a
support anal
support nal
interim analsupport interim anal yssupport ysany s after last any s after last applicationany application
be set to December 31st of the given any be set to December 31st of the given marketing present: If the maximum of the subject’s date of study
marketing present: If the maximum of the subject’s date of study
termination or the date equivalent to 30 day
marketing termination or the date equivalent to 30 day
medication is the same year as the occurrence of the AE/Concomitant medication, then the 
marketing medication is the same year as the occurrence of the AE/Concomitant medication, then the 
 and month will be set to the maximum of the date of studmarketing  and month will be set to the maximum of the date of stud
applicationmarketing applicationauthorization of study medication. Otherwise the start day
authorization of study medication. Otherwise the start day
ear present: The end day
authorization ear present: The end day
present: If the maximum of the subject’s date of studyauthorization present: If the maximum of the subject’s date of studyapplication  of the month.
application  of the month.
ear present: If the start of study
application ear present: If the start of study
ear as the occurrence of the AE/concomitant medication, the start day
application ear as the occurrence of the AE/concomitant medication, the start day
of study medication. Otherwise the start dayapplication of study medication. Otherwise the start dayand  of first application
and  of first application
 of the month.and  of the month.any y medication occurred in the 
any y medication occurred in the 
ear as the occurrence of the AE/concomitant medication, the start dayany ear as the occurrence of the AE/concomitant medication, the start day
 of first applicationany  of first applicationextensions the algorithms listed below will be followed. Start and stop dates of AEs or 
extensions the algorithms listed below will be followed. Start and stop dates of AEs or 
ed as reported in the subject data listings (i.e., no imputed 
extensions ed as reported in the subject data listings (i.e., no imputed 
y medication occurred in the extensions y medication occurred in the or -reported start and stop dates for AEs and or -reported start and stop dates for AEs and 
the algorithms listed below will be followed. Start and stop dates of AEs or or the algorithms listed below will be followed. Start and stop dates of AEs or variations ion usage, a complete date must be established in 
variations ion usage, a complete date must be established in 
-reported start and stop dates for AEs and variations -reported start and stop dates for AEs and thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 18of 39provide additional information on the efficacy  analy sis and will describe findings in a subset of 
subjects who more closely followed the intentions of the study  protocol.
4.7 Active-control studies intended to s how equivalence
This section is not applicable f or this study .
4.8 Examination of s ubgroups
No subgroups are defined for this study.
5 STUDY POPULA TION CHA RACTERISTICS
5.1 Subject disposition
Subject disposition will be summarized on all subjects screened. The number of subjects 
screened, in addition to the number and percentage of those subjects who were screen failures, 
broken down b y primary  reason for screen failure, will be presented.
A summary  of disposition of subjects will be provided for all screened subjects. The date of first 
subject in, date of last subject out, number of subjects screened, and the number of subjects in each anal ysis set bygroup and for all subjects will be summarized overall and by investigator 
site. Subjects who transferred sites will be summarized according to their original si te.
A summary  of disposition of anal ysis sets will be provided for the SS. Additionally , a summary  
of disposition and discontinuation reasons will present the number and percentage of subjects starting the stud y, completing the study, and discontinuing the study  with primary  reason for 
discontinuation.
A summary  of discontinuations due to AEs for the SS will present the number and percentage of 
subjects who discontinued this study  due to AEs broken down by  type of AE. 
The following listings will be provide d: study eligibility  criteria text, subjects who did not meet 
study  eligibility  criteria, subject disposition, subject anal ysis sets, Neupro discontinuation and 
visit dates.
5.2 Protocol deviations
Important protocol deviations defined in the protocol- specific document, and additionally  
identified at the data evaluation meetings, will be listed. In addition, the number and percentage 
of subjects with at least 1 important protocol deviation will be summarized overall and b y 
category  of important protocol deviation for the SS. The number and percentage of subjects with 
no important protocol deviations will also be summarized for the SS. These will be summarizedby group and for all subjects overall. A listing of important protocol deviations will be provided.REDACTED of disposition and discontinuation reasons will present the number and percentage of subjects 
REDACTED of disposition and discontinuation reasons will present the number and percentage of subjects 
y, and discontinuing the
REDACTED y, and discontinuing the
 of discontinuations due to AEs for the SS will present the number and percentage of 
REDACTED  of discontinuations due to AEs for the SS will present the number and percentage of 
subjects who discontinued this studyREDACTED subjects who discontinued this study  due to AEs broken down byREDACTED  due to AEs broken down by subjects who discontinued this study  due to AEs broken down by subjects who discontinued this studyREDACTED subjects who discontinued this study  due to AEs broken down by subjects who discontinued this studyCOPY is sets will be provided for the SS. Additionally
COPY is sets will be provided for the SS. Additionally
of disposition and discontinuation reasons will present the number and percentage of subjects COPY of disposition and discontinuation reasons will present the number and percentage of subjects 
y, and discontinuing theCOPY y, and discontinuing the
This document cannot  group and for all subjects overall. A listing of important protocol deviations will be provided.
cannot  group and for all subjects overall. A listing of important protocol deviations will be provided.be  of important protocol deviati
be  of important protocol deviati
no important protocol deviations will also be summarized for the SS. be no important protocol deviations will also be summarized for the SS. 
 group and for all subjects overall. A listing of important protocol deviations will be provided.be  group and for all subjects overall. A listing of important protocol deviations will be provided.used of subjects with at least 1 important protocol deviation will be summarized overall and b
used of subjects with at least 1 important protocol deviation will be summarized overall and b
 of important protocol deviatiused  of important protocol deviati
no important protocol deviations will also be summarized for the SS. used no important protocol deviations will also be summarized for the SS. to identified at the data evaluation meetings, will be listed. Ito identified at the data evaluation meetings, will be listed. I
of subjects with at least 1 important protocol deviation will be summarized overall and bto of subjects with at least 1 important protocol deviation will be summarized overall and bsupport Protocol d
support Protocol d eviations
support eviations
Important protocol deviations defined in the protocolsupport Important protocol deviations defined in the protocol
identified at the data evaluation meetings, will be listed. I support identified at the data evaluation meetings, will be listed. Iany eviationsany eviationsmarketing  of discontinuations due to AEs for the SS will present the number and percentage of 
marketing  of discontinuations due to AEs for the SS will present the number and percentage of 
 due to AEs broken down by
marketing  due to AEs broken down by
The following listings will be provide
marketing The following listings will be provide d: 
marketing d: study
marketing study
 criteria, subject disposition, subject analmarketing  criteria, subject disposition, subject analauthorization is sets will be provided for the SS. Additionally
authorization is sets will be provided for the SS. Additionally
of disposition and discontinuation reasons will present the number and percentage of subjects 
authorization of disposition and discontinuation reasons will present the number and percentage of subjects 
y, and discontinuing the
authorization y, and discontinuing the
 of discontinuations due to AEs for the SS will present the number and percentage of authorization  of discontinuations due to AEs for the SS will present the number and percentage of 
 due to AEs broken down byauthorization  due to AEs broken down byapplication st subject out, number of subjects screened, and the number of subjects in 
application st subject out, number of subjects screened, and the number of subjects in 
group and for all subjects will be summarized overall and by
application group and for all subjects will be summarized overall and by
who transferred sites will be summarized according to their original si
application who transferred sites will be summarized according to their original si
is sets will be provided for the SS. Additionallyapplication is sets will be provided for the SS. Additionally
of disposition and discontinuation reasons will present the number and percentage of subjects application of disposition and discontinuation reasons will present the number and percentage of subjects and  of disposition of subjects will be provided for all screened subjects. The date of first 
and  of disposition of subjects will be provided for all screened subjects. The date of first 
st subject out, number of subjects screened, and the number of subjects in and st subject out, number of subjects screened, and the number of subjects in any  of disposition of subjects will be provided for all screened subjects. The date of first any  of disposition of subjects will be provided for all screened subjects. The date of first extensions Subject disposition will be summarized on all subjects screened. The number of subjects 
extensions Subject disposition will be summarized on all subjects screened. The number of subjects 
number and percentage of those subjects who were screen failures, extensions number and percentage of those subjects who were screen failures, or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 19of 396 DEM OGRA PHICS AND OTH ER BASELINE 
CHA RACTERISTICS
6.1 Demographics
Tables with descriptive statistics and listings will be given for the demographic variables age, 
gender, weight and height at Baseline, race, ethnicity, and body  mass index (BMI). Demographic 
characteristic s will be summarized for all study defined analy sis sets, and presented in a listing.
The calculation of age is based on the date of informed consent and the date of birth. If the date of birth is incomplete, it will be completed with January  asimputed month if month is missing 
and it will be completed with 1 as imputed day  of birth if day is missing. A ge is calculated as 
follows: Age (y ears) = ([Date of Informed Consent] – [Imputed Date of Birth]) / 365.25 . It will 
be summarized as a continuous variable and as a categorical variable based on the categories: 
<65 y ears, 65- <85 years,≥85 years, also based on the categories: <65 years, ≥65 y ears, and also 
based on the categories: <75 years, ≥75 y ears.
Weight recorded in pounds (lb) will be converted to kilograms (kg) as weight(lb)*0.4536kg/lb.
Height recorded in inches (in) will be converted to height in centimeters (cm) as 
height(in)*2.54cm/in.
The BMI will be calculated using the following formula (Keys et al, 1972):
22
(cm) height (kg) weight * 10000) (kg/m BMI 
  
6.2 Other B aseline characteristics
The disease stage of Parkinson’s Disease at Baseline can be assessed by the given start dose of 
Neupro at either 2mg/24h or 4mg/24h. The start dose of Neupro is tabulated within the study  
medication summary .
6.3 Medical h istory  and concomitant diseases
Medical history data and concomitant diseases data are not collected. Therefore this section is not applicable.
6.4 Prior and c oncomitant medications
Medications will be considered as prior if the start date of the medication is before the date of first patch administration. Medications will be considered as concomitant if they are taken at 
least once in the treatment period starting with the first patch administration and ending after the 
last patch administration during the stud y. Medications starting prior to first patch a dministration
and continuing into the treatment period will be considered both prior and concomitant 
medication.
In case of partial or missing dates the rules described in Section 4.2 will be applied.
Prior and concomitant medications will be summarized separatel y for the SS. The number and 
percent age of subjects who used prior and concomitant medications, respectivel y, will be 
presented according to the anatomical main group (level 1), the pharmacological subgroup 
(level 3), and the preferred term.REDACTED   
REDACTED   
haracteristics
REDACTED haracteristics
The disease stage of Parkinson’s Disease at Baseline can be assessed b REDACTED The disease stage of Parkinson’s Disease at Baseline can be assessed bCOPY The BMI will be calculated using the following formula (Keys et al, 1972):
COPY The BMI will be calculated using the following formula (Keys et al, 1972):
This document and continuing into the treatment period will be considered both prior and concomitant 
document and continuing into the treatment period will be considered both prior and concomitant 
medication.
document medication.
In case of partial or missing dates t
document In case of partial or missing dates tcannot least once in the treatment period starting with the first patch administration an
cannot least once in the treatment period starting with the first patch administration an
cannot last patch 
cannot last patch administration
cannot administration
and continuing into the treatment period will be considered both prior and concomitant cannot and continuing into the treatment period will be considered both prior and concomitant be first patch administration. Medications will be considered as concomitant if they
be first patch administration. Medications will be considered as concomitant if they
least once in the treatment period starting with the first patch administration an be least once in the treatment period starting with the first patch administration anused Medications will beused Medications will be
first patch administration. Medications will be considered as concomitant if they used first patch administration. Medications will be considered as concomitant if theyto Prior and cto Prior and csupport  data and concomitant diseases data are not collected. Therefore this section is 
support  data and concomitant diseases data are not collected. Therefore this section is 
Prior and csupport Prior and cany istoryany istory  and any  and istory  and istoryany istory  and istory
 data and concomitant diseases data are not collected. Therefore this section is any  data and concomitant diseases data are not collected. Therefore this section is marketing The disease stage of Parkinson’s Disease at Baseline can be assessed b
marketing The disease stage of Parkinson’s Disease at Baseline can be assessed b
marketing Neupro at either 2mg/24h or 4mg/24h. The start dose
marketing Neupro at either 2mg/24h or 4mg/24h. The start dose
 and marketing  and authorization haracteristicsauthorization haracteristicsapplication Height recorded in inches (in) will be converted to height in centimeters (cm) as 
application Height recorded in inches (in) will be converted to height in centimeters (cm) as 
The BMI will be calculated using the following formula (Keys et al, 1972):application The BMI will be calculated using the following formula (Keys et al, 1972):and Weight recorded in pounds (lb) will be converted to kilograms (kg) as weight(lb)*0.4536kg/lb.and Weight recorded in pounds (lb) will be converted to kilograms (kg) as weight(lb)*0.4536kg/lb.any extensions if month is missing 
extensions if month is missing 
ge is calculated as 
extensions ge is calculated as 
mputed Date of Birth]) / 365.25
extensions mputed Date of Birth]) / 365.25
based on the categories: 
extensions based on the categories: 
≥65 yextensions ≥65 yor if month is missing or if month is missing 
ge is calculated as or ge is calculated as variations  mass index (BMI). Demographic 
variations  mass index (BMI). Demographic 
, and presented in a listing.
variations , and presented in a listing.
calculation of age is based on the date of informed consent and the date of birth. If the date variations calculation of age is based on the date of informed consent and the date of birth. If the date 
if month is missing variations if month is missing thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 20of 397 MEA SUREMENTS OF TREA TMENT COM PLIA NCE
A calculation of treatment compliance will not be performed. This is due to the nature of this 
pilot study . Subjects in both treatment arms are treated using standard clinical practice onl y, 
there is no fixed mandatory  dosing scheme to be followed. Also, no diary data or drug 
accountability  data is collected. Data on Neupro dosing is recorded on the concomitant 
medication pages of the CRF only . Given this, an appropriate measure for treatment compliance 
could not be identified.
8 EFFICA CY ANAL YSES
The efficacy anal ysis will be performed on the FAS and observed cases will be utilized. The PPS 
will be used for sensitivity anal ysis on selected efficacy  variables.
8.1 Statistical analy sis of the primary  efficacy  variable s
The change from Baseline to Visit 2 in the primary efficacy variables will be anal yzed for 
differences among the treatment groups using analysis of covariance (ANCOVA) with treatment 
group and center as factors and the corresponding baseline variable as a covariate. The 95% 
confidence interval (CI) on the calculated least square mean difference between experimental 
group and control group in change from baseline in the primary  efficacy  variables will also be 
reported.
8.1.1 Derivations of primary efficacy  variable s
8.1.1.1 Unified Parkinson’s Disease Rating Scale Part III
The Un ified Parkinson’s Disease Rating Scale (UPDRS; Movement Disorder Societ y Task Force 
on Rating Scales for Parkinson’s disease, 2003) consists of 4 parts: PartI of UPDRS assesses 
mentation, behavior, and mood. Part IIof the UPDRS assesses the subject’s activity of daily  
living. Part III assesses motor function. Part IV assesses complications of therap y.
The UPDRS Part III (motor subscale) will be measured in the “on” state and consists of 27 items 
and sub-items scored between 0 and 4. It includes speech, facial expression, tremor at rest (face, 
right hand, left hand, right foot, left foot), action or postural tremor of hands (right and left), rigidity  (neck, extremities), finger taps (right and left), hand movements (right and left), rapid 
alternating movements of hands (right and left), leg agilit y (right and left), arising from chair, 
posture, gait, postural stability , body  brady kinesia, and hy pokinesia (14 items, 27 questions = 
108 points maximum). The sum score will be calculated as sum of the 27 indi vidual scores. If 
one or more items are missing, the sum score will also be missing.
8.1.1.2 Kinesia -ONE variables
The Kinesia-ONE data includes the following variables collected at Baseline and at Visit 2:
finger tapping speed score
rest tremor score
averaged fin ger tapping speed and resting tremor scores
postural tremor score
finger tapping amplitude scoreREDACTED Unified Parkinson’s Disease Rating Scale Part III
REDACTED Unified Parkinson’s Disease Rating Scale Part III
ified Parkinson’s Disease Rating Scale (UPDRS; 
REDACTED ified Parkinson’s Disease Rating Scale (UPDRS; 
’s disease, 2003) 
REDACTED ’s disease, 2003) 
mentation, behavior, and mood. Part REDACTED mentation, behavior, and mood. Part IIREDACTED IIof the UPDRS assesses the subject’s REDACTED of the UPDRS assesses the subject’s COPY ns of primary efficacyCOPY ns of primary efficacy  vCOPY  v ns of primary efficacy  v ns of primary efficacyCOPY ns of primary efficacy  v ns of primary efficacy ariableCOPY ariable
This document 
document finger tapping speed score
document finger tapping speed score

document cannot The Kinesia
cannot The Kinesia
finger tapping speed scorecannot finger tapping speed scorebe one or more items are missing, the sum score will also be missing.
be one or more items are missing, the sum score will also be missing. used posture, gait, postural stability
used posture, gait, postural stability
108 points maximum). The sum score will be calculated as sum of the 27 indi
used 108 points maximum). The sum score will be calculated as sum of the 27 indi
used one or more items are missing, the sum score will also be missing. used one or more items are missing, the sum score will also be missing.to posture, gait, postural stabilityto posture, gait, postural stability
108 points maximum). The sum score will be calculated as sum of the 27 indito 108 points maximum). The sum score will be calculated as sum of the 27 indisupport right hand, left hand, right foot, left foot), action or postural tremor of hands (right and left), 
support right hand, left hand, right foot, left foot), action or postural tremor of hands (right and left), 
 (neck, extremities), finger taps (right and left), hand movements (right and left), rapid 
support  (neck, extremities), finger taps (right and left), hand movements (right and left), rapid 
vements of hands (right and left), leg agilitsupport vements of hands (right and left), leg agilit
posture, gait, postural stabilitysupport posture, gait, postural stabilityany items scored between 0 and 4.
any items scored between 0 and 4.
right hand, left hand, right foot, left foot), action or postural tremor of hands (right and left), any right hand, left hand, right foot, left foot), action or postural tremor of hands (right and left), marketing ’s disease, 2003) 
marketing ’s disease, 2003) 
of the UPDRS assesses the subject’s 
marketing of the UPDRS assesses the subject’s 
III assesses motor function. Part IV assesses complications of therap
marketing III assesses motor function. Part IV assesses complications of therap
The UPDRS Part III (motor subscale) will be measured in the “on” state and consists of 27 items marketing The UPDRS Part III (motor subscale) will be measured in the “on” state and consists of 27 items 
items scored between 0 and 4.marketing items scored between 0 and 4.authorization ariable
authorization ariable
Unified Parkinson’s Disease Rating Scale Part III
authorization Unified Parkinson’s Disease Rating Scale Part III
ified Parkinson’s Disease Rating Scale (UPDRS; 
authorization ified Parkinson’s Disease Rating Scale (UPDRS; 
’s disease, 2003) authorization ’s disease, 2003) consists of 4 parts: authorization consists of 4 parts: application group and center as factors and the corresponding baseline variable as a covariate. The 95% 
application group and center as factors and the corresponding baseline variable as a covariate. The 95% 
ed least square mean difference between experimental 
application ed least square mean difference between experimental 
group and control group in change from baseline in the primary
application group and control group in change from baseline in the primary  efficacy
application  efficacy group and control group in change from baseline in the primary  efficacy group and control group in change from baseline in the primary
application group and control group in change from baseline in the primary  efficacy group and control group in change from baseline in the primary
ariableapplication ariableand sis of covariance (ANCOVA) with treatment 
and sis of covariance (ANCOVA) with treatment 
group and center as factors and the corresponding baseline variable as a covariate. The 95% and group and center as factors and the corresponding baseline variable as a covariate. The 95% any The change from Baseline to Visit 2 in the primary efficacy variables will be analany The change from Baseline to Visit 2 in the primary efficacy variables will be anal
sis of covariance (ANCOVA) with treatment any sis of covariance (ANCOVA) with treatment extensions is will be performed on the FAS and observed cases will be utilized. The PPS 
extensions is will be performed on the FAS and observed cases will be utilized. The PPS 
ariableextensions ariable sextensions sor is will be performed on the FAS and observed cases will be utilized. The PPS or is will be performed on the FAS and observed cases will be utilized. The PPS variations . Given this, an appropriate measure for treatment compliance 
variations . Given this, an appropriate measure for treatment compliance thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 21of 39hand grasp speed score
hand grasp amplitude score
rapid alternating movement speed score
rapid alternating amplitude score
dyskinesia score
kinetic tremor score
rapid alternating movement rhy thm score
hand movements rh ythm score
finger tapping rh ythm score
These scores are all calculated as an average from triplicate repeated assessments at a 
measurement point. 
In addition, a composite Kinesia-ONE score will be calculated as the average of following 
scores: 
finger tapping speed score
rest tremor score
postural tremor score
kinetic tremor score
finger tapping amplitude score
finger tapping rh ythm score
hand grasp speed score
hand grasp amplitude score
hand grasp rh ythm score
rapid alternating movement speed score
rapid alternating amplitude score
rapid alternating rh ythm score
The composite score will only be calculated if at least 50% of the scores are available.
8.1.1.3 Number of Neupro dose changes
The number of Neupro dose changes is derived as the sum of all Neupro dose changes during the 
treatment period and includes an y increase or decrease of dose, irrespective of the dose level. If a 
dose level change, e.g. from 2mg/24h to 4mg/24h, occurs multiple times, it is counted as often as 
it occurs. REDACTED COPY 
This document The number of 
document The number of 
treatment period and includes an
document treatment period and includes ancannot The composite score will only
cannot The composite score will only
cannot 8.1.1.3cannot 8.1.1.3be rapid alternating rh
be rapid alternating rh
The composite score will only be The composite score will onlyused rapid alternating amplitude score
used rapid alternating amplitude score
rapid alternating rh used rapid alternating rhto rapid alternating movement speed score
to rapid alternating movement speed score
rapid alternating amplitude score to rapid alternating amplitude scoresupport hm score
support hm score
rapid alternating movement speed scoresupport rapid alternating movement speed scoreany hand grasp amplitude scoreany hand grasp amplitude scoremarketing authorization application ll be calculated as the average of following 
application ll be calculated as the average of following and ll be calculated as the average of following and ll be calculated as the average of following any repeated assessments at a 
any repeated assessments at a extensions repeated assessments at a extensions repeated assessments at a or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 22of 398.1.2 Primary a nalysis of the primary e fficacy  variables
The efficacy  variables, change from Baseline to Visit 2 (for all continuous efficacy  variables not 
based on Kinesia-360, i.e. UPDRS Part III and Kinesia-ONE scores) will be anal yzed utilizing 
an anal ysis of covariance (ANCOVA) with Baseline as a covariate, “center” as factor, and 
“group” as main factor. The 2 groups are the Experimental Group (EG) and the Control Group 
(CG).
The 2- sided null and alternative hy potheses are: 
Null hy pothesis (H 0): EG=CG
Alternative h ypothesis (H a): EG ≠CG
EG: Represents the change from Baseline to Visit 2 for subjects in the Experimental Group.
CG: Represents the change from Baseline to Visit 2 for subjects in the Control Group.The efficacy anal ysis will be performed on the FAS and observed cases will be utilized. The 
group effect will be estimated and presented with 95% 2-sided CIs and p- values.
The single items of UPDRS Part III and the sum score will be presented in listings, the sum score 
will be summarized by  group, and the change from Baseline to Visit 2 in UPDRS Part III score 
will be anal yzed using ANCOVA.
The change from Baseline to Visit 2 in each of the Kinesia- ONE scores will be anal yzed using 
ANCOVA.
The Neupro dose per 24h at Visit 2 will be summarized by group, as well as the Neupro starting 
dose per 24h. Both assessments of Neupro dose will be related in a shift table by  group. In 
addition, Neupro dose and Neupro dose change will be tabulated as continuous variable.
The number of Neupro dose changes after first administration until Visit 2 will be summarized 
by group.
The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
study  for the control group and the experimental group will be performed using logistic 
regression with factors for treatment and center.
8.1.3 Secondary  analyses of the primary  efficacy variable s
Not applicable.
8.1.4 Supportive and sensitivity a nalyses of the primary  efficacy  variable s
The primary anal yses (ANCOVA and corresponding summary statistics) will be repeated for the 
PPS on observed cases.
In case of misallocation to treatment groups, the primary  anal yses will be repeated for the FAS 
as randomized.
8.2 Analysis of other efficacy  variable s
8.2.1 Kinesia -360 motor scores
Kinesia-360- based efficacy  data will be presented descriptivel y for the Experimental Group. Due 
to repeated measurements (during titration weekly and during maintenance), comparisons will be REDACTED The Neupro dose per 24h at Visit 2 will be summarized by
REDACTED The Neupro dose per 24h at Visit 2 will be summarized by
dose per 24h. Both assessments of Neupro dose will be related in a shift table by
REDACTED dose per 24h. Both assessments of Neupro dose will be related in a shift table by
and Neupro dose REDACTED and Neupro dose change will beREDACTED change will beCOPY The change from Baseline to Visit 2 in each of the KinesiaCOPY The change from Baseline to Visit 2 in each of the Kinesia
This document In case of misallocation to treatment groups, the primary
document In case of misallocation to treatment groups, the primary
as randomized.
document as randomized.cannot The primary
cannot The primary
cannot PPS on observed cases.
cannot PPS on observed cases.
In case of misallocation to treatment groups, the primarycannot In case of misallocation to treatment groups, the primarybe The primarybe The primary  analbe  anal The primary  anal The primarybe The primary  anal The primaryused Supportive and used Supportive and to Secondary
to Secondary support group and the experimental group will be performed using 
support group and the experimental group will be performed using 
regression with factors for treatment and center
support regression with factors for treatment and center
Secondary support Secondaryany The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
any The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
group and the experimental group will be performed using any group and the experimental group will be performed using marketing change will be
marketing change will be
after first administration until Visit 2 will be summarized 
marketing after first administration until Visit 2 will be summarized 
The comparison of the rate of discontinuation of treatment with Neupro during the course of the marketing The comparison of the rate of discontinuation of treatment with Neupro during the course of the authorization The change from Baseline to Visit 2 in each of the Kinesia
authorization The change from Baseline to Visit 2 in each of the Kinesia
The Neupro dose per 24h at Visit 2 will be summarized by
authorization The Neupro dose per 24h at Visit 2 will be summarized by
dose per 24h. Both assessments of Neupro dose will be related in a shift table byauthorization dose per 24h. Both assessments of Neupro dose will be related in a shift table by
change will beauthorization change will beapplication re will be presented in listings, the sum score 
application re will be presented in listings, the sum score 
change from Baseline to Visit 2 in UPDRS Part III score 
application change from Baseline to Visit 2 in UPDRS Part III score 
The change from Baseline to Visit 2 in each of the Kinesia application The change from Baseline to Visit 2 in each of the Kinesia -application -ONEapplication ONEand is will be performed on the FAS and observed cases will be utilized. The 
and is will be performed on the FAS and observed cases will be utilized. The 
sided CIs and pand sided CIs and pany or subjects in the Control Group.
any or subjects in the Control Group.
is will be performed on the FAS and observed cases will be utilized. The any is will be performed on the FAS and observed cases will be utilized. The 
values.any 
values.extensions 2 for subjects in the Experimental Group.
extensions 2 for subjects in the Experimental Group.
or subjects in the Control Group. extensions or subjects in the Control Group.or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 23of 39performed b y time point and also by dose, if applicable (dependent on number of subjects in 
respective dose groups). Optional time points might also be subject to analysis (dependent on 
number of subjects at respective time points or windows for time points).
Change from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores 
derived from the Kinesia-360 wearable technology  by Neupro dose level (mg/24h) for the 
Experimental Group will be summarized for following scores:
average daily tremor score
average dail y slowness score
average dail y dyskinesia score
percent wear-time tremor detected
percent wear- time dy skinesia detected
percent wear- time user not moving
percent wear-time user was walking score
percent wear-time user active but not walking
number of steps per hour while wearing device
The average daily scores of tremor, slowness and dy skinesia will be derived from the 2-minutes 
interval data. Only those 2 -minutes interval data records, when the device was not paused, will 
be considered. For each day , starti ng at 0:00 until 23:58, the available non- paused 2- minutes 
interval scores of tremor (and similarly  for slowness and dy skinesia) will be selected and the 
arithmetic mean of these will be calculated which results in the average daily  scores. 
The percent we ar-times and number of steps per hour will be derived from the daily  Kinesia -360 
data. Multiple records per day will be averaged and weighted by  wear- time.
These dail y scores will be used to derive the scores per visit week. The daily  scores will be 
averaged from 2 consecutive day s of wear ing in the respective assessment week. Assessments on 
study  day 8 to 14 are eligible for Week 2 scores, assessments on study  day 15 to 21 are eligible 
for Week 3 scores, assessments on study  day 22 to 28 are eligible for Week 4 scores, 
assessments on study  day 43 to 56 are eligible for Week 7/8 scores, and assessments on study  
day 71 to 77 are eligible for Week 11 assessments. The Week 7/8 is an artificial lyadded Week, 
which considers the data collected on voluntary  basis during that time interval, and therefore 
might have sparse data. If more than 2 consecutive assessments are available for Week 7/8, the 
latest 2 consecutive values will be considered. The same applies for the assessments in Week 2, 
Week 3, Week 4, and Week 11: If more than 2 consecutive assessments are available per week, 
the latest 2 consecutive values will be considered.
In addition, the maximum relative day of Kinesia -360 usage will be listed, and the number of 
days the subject used the Kinesia-360 device will be calculated by subject and summarized.
8.2.2 Parkinson’s Disease Questionnaire (PDQ- 39)
The Parkinson’s Disease Questionnaire (PDQ-39; Jenkinson, 1997) is a simple questionnaire that 
assesses health related quality of life in individuals with PD. The answer categories are coded as 
follows: 0=never, 1=occasionally , 2=sometimes, 3=often, 4=alway s or cannot do at all. It REDACTED -minutes interval data records, when the device was not paused, will 
REDACTED -minutes interval data records, when the device was not paused, will 
ng at 0:00 until 23:58, the available non-
REDACTED ng at 0:00 until 23:58, the available non-
 for slowness and dy
REDACTED  for slowness and dy
arithmetic mean of these will be calculated which results in the average daily
REDACTED arithmetic mean of these will be calculated which results in the average daily
times and number of steps per hour will be derived from the dailyREDACTED times and number of steps per hour will be derived from the dailyCOPY  scores of tremor, slowness and dyCOPY  scores of tremor, slowness and dy skinesia will be derived from the 2COPY skinesia will be derived from the 2
-minutes interval data records, when the device was not paused, will COPY -minutes interval data records, when the device was not paused, will 
This document the latest 2 consecutive values will be considered.
document the latest 2 consecutive values will be considered.
In addition, 
document In addition, cannot latest 2 consecutive values will be considered. 
cannot latest 2 consecutive values will be considered. 
cannot Week 3, Week 4, and Week
cannot Week 3, Week 4, and Week
the latest 2 consecutive values will be considered.cannot the latest 2 consecutive values will be considered.be which considers the data collected on voluntary
be which considers the data collected on voluntary
might have sparse data. be might have sparse data. 
latest 2 consecutive values will be considered. be latest 2 consecutive values will be considered. used 77 are eligible for Week 11 assessments. 
used 77 are eligible for Week 11 assessments. 
which considers the data collected on voluntaryused which considers the data collected on voluntary
might have sparse data. used might have sparse data. to assessments on studyto assessments on study  day 43 to 56 are eligible for Week 7/8 scores, to  day 43 to 56 are eligible for Week 7/8 scores, assessments on study  day 43 to 56 are eligible for Week 7/8 scores, assessments on studyto assessments on study  day 43 to 56 are eligible for Week 7/8 scores, assessments on study
77 are eligible for Week 11 assessments. to 77 are eligible for Week 11 assessments. support consecutive day
support consecutive day
 8 to 14 are eligible for Week 2 scores, assessments on study
support  8 to 14 are eligible for Week 2 scores, assessments on study
for Week 3 scores, assessments on studysupport for Week 3 scores, assessments on study
 day 43 to 56 are eligible for Week 7/8 scores, support  day 43 to 56 are eligible for Week 7/8 scores, any y scores will be used to derive the scores per visit week. 
any y scores will be used to derive the scores per visit week. 
consecutive day any consecutive day s of wearany s of wearmarketing arithmetic mean of these will be calculated which results in the average daily
marketing arithmetic mean of these will be calculated which results in the average daily
times and number of steps per hour will be derived from the daily
marketing times and number of steps per hour will be derived from the daily
 will be averaged and weighted by
marketing  will be averaged and weighted by
y scores will be used to derive the scores per visit week. marketing y scores will be used to derive the scores per visit week. authorization skinesia will be derived from the 2
authorization skinesia will be derived from the 2
-minutes interval data records, when the device was not paused, will 
authorization -minutes interval data records, when the device was not paused, will 
ng at 0:00 until 23:58, the available non-
authorization ng at 0:00 until 23:58, the available non-
 for slowness and dy
authorization  for slowness and dy
arithmetic mean of these will be calculated which results in the average daily authorization arithmetic mean of these will be calculated which results in the average dailyapplication skinesia will be derived from the 2application skinesia will be derived from the 2and any extensions or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 24of 39provides scores in 8 scales: mobility (questions 1-10), activities of dail y living (questions 11- 16), 
emotions (questions 17-22), stigma ( questions 23-26), social support (questions 27 -29), 
cognition (questions 30- 33), communication (questions 34-36) , and bodily discomfort (questions 
37-39). It is designed for self- completion by  subjects and should take onl y a few minutes for the 
subject to complete. 
For each of the 8 domains a score will be calculated: The coded answer categories of the 
corresponding domain questions will be added. This domain raw value will be multiplied with 
100 and divided by the maximum domain raw value (e.g. 4*10=40 for the 10 questions of 
mobility  domain). This transformation gives domain scores between 0 and 100.
Domain scores will only be calculated if at least 50% of items on the scale have been answered. 
If this is the case, the missing items , if an y,will be replaced with the overall mean of the item, 
and the corresponding domain score will be calculated based on the replaced questions.  
The social support domain consists of questions 27, 28, and 29. If respondents indicate that they 
do not have a spouse or partner on question 28 then social support will be calculated as follows: 
social support = (sum of questions 27 + 29) / (4 * 2) * 100.
Individual ques tions will be summarized categorical ly,and the domain scores will be tabulated 
using continuous summary statistics by visit. 
A sum score, calculated by adding together the 8 domain scores and dividing the sum by  8, will 
also be presented using continuous summary statistics by  visit (including change from baseline 
values).
8.2.3 Patient A ctivation Measure (PA M-13)
The Patient Activation Measure (PAM- 13) quantifies the extent to which people are informed 
about and involved in their health care. The answer categories are coded as follows: 1=disagree 
strongl y, 2=disagree, 3=agree, 4=agree strongl y. 
A sum score will be calculated by adding together t he coded answer categories of the 13 items, 
and then transforming to a scale from 0 to 100 using the formula 100*(sum of items - 13)/(52-
13). 
The sum score will onl y be calculated if at least nine questions have been answered. If this is the 
case, the missing items, if any, will be replaced with the overall mean of the item, and the sum 
score will be calculated based on the replaced items.
The individual questions will be summarized categorically, and the sum score will be presents 
using continuous summary  statistics by  visit (including change from baseline values).
8.2.4 Unified Parkinson’s Disease Rating Scale Parts I, II, IV
The UPDRS Part I  (Mentation, Behavior, and Mood) includes intellectual impairment, thought 
disorder, depression, and motivation/initiative (4 questions=16 points maximum).
The UPDRS Part II (Activities in Daily  Living) consists of 13 items scored between 0 and 4. It 
includes speech, salivation, swallowing, handwriting, cutting food and handling utensils, 
dressing, h ygiene, turning in bed and adjusting clothes, falling (unrelated to freezing), freezing 
when walking, walking, tremor, and sensory  complaints r elated to Parkinsonism (13 REDACTED ation Measure (PA
REDACTED ation Measure (PA
The Patient Activation Measure (PAM
REDACTED The Patient Activation Measure (PAM -
REDACTED -13) 
REDACTED 13) 
about and involved in their health care REDACTED about and involved in their health care . The answer categorREDACTED . The answer categorCOPY  adding together the 8 domain scores and dividing the sum by
COPY  adding together the 8 domain scores and dividing the sum by
 statistics byCOPY  statistics by
This document The UPDRS Part I
document The UPDRS Part I
disorder, depression, and motivation/initiative (4 questions=16 points maximum).
document disorder, depression, and motivation/initiative (4 questions=16 points maximum).cannot using continuous summary
cannot using continuous summary
The UPDRS Part Icannot The UPDRS Part Ibe The individual questions will be summarized categorically
be The individual questions will be summarized categorically
using continuous summary be using continuous summaryused score will be calculated based on 
used score will be calculated based on 
The individual questions will be summarized categorically used The individual questions will be summarized categoricallyto case, the missing items, if anto case, the missing items, if an
score will be calculated based on to score will be calculated based on support y 
support y be calculated if at least nine questions have been answered. 
support be calculated if at least nine questions have been answered. 
case, the missing items, if an support case, the missing items, if anany by
any by adding together t
any  adding together tby adding together tby
any by adding together tby
and then transforming to a scale from 0 to 100 using the formula 100*(sum any and then transforming to a scale from 0 to 100 using the formula 100*(sum marketing 13) 
marketing 13) quantifies the extent to which people are informed 
marketing quantifies the extent to which people are informed 
. The answer categor
marketing . The answer categor
y, 2=disagree, 3=agree, 4=agree strongl
marketing y, 2=disagree, 3=agree, 4=agree strongl
 adding together tmarketing  adding together tby adding together tbymarketing by adding together tbyauthorization  adding together the 8 domain scores and dividing the sum by
authorization  adding together the 8 domain scores and dividing the sum by
 statistics by
authorization  statistics by  visit (including change from baseline 
authorization  visit (including change from baseline  statistics by  visit (including change from baseline  statistics by
authorization  statistics by  visit (including change from baseline  statistics by
ation Measure (PA
authorization ation Measure (PA
quantifies the extent to which people are informed authorization quantifies the extent to which people are informed application the domain scores will be tabulated 
application the domain scores will be tabulated 
 adding together the 8 domain scores and dividing the sum byapplication  adding together the 8 domain scores and dividing the sum by
 visit (including change from baseline application  visit (including change from baseline and do not have a spouse or partner on question 28 then social support will be calculated as follows: 
and do not have a spouse or partner on question 28 then social support will be calculated as follows: any rt domain consists of questions 27, 28, and 29. If respondents indicate that they
any rt domain consists of questions 27, 28, and 29. If respondents indicate that they
do not have a spouse or partner on question 28 then social support will be calculated as follows: any do not have a spouse or partner on question 28 then social support will be calculated as follows: extensions east 50% of items on the scale have been answered. 
extensions east 50% of items on the scale have been answered. 
will be replaced with the overall mean of the item, 
extensions will be replaced with the overall mean of the item, 
and the corresponding domain score will be calculated based on the replaced questions.  
extensions and the corresponding domain score will be calculated based on the replaced questions.  
rt domain consists of questions 27, 28, and 29. If respondents indicate that theyextensions rt domain consists of questions 27, 28, and 29. If respondents indicate that theyor variations This domain raw value will be multiplied with 
variations This domain raw value will be multiplied with thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 25of 39questions=52 points maximum). The sum score will be calculated as the sum of the 13 individual 
scores. If one or more items are missing, the sum score will also be missing.
The UPDRS Part IV (Complications of Therapy) consists of 11 questions. It includes 
dyskinesias, duration, disability , painful d yskinesias, earl y morning d ystonia, clinical 
fluctuations, presence of anorexia, nausea or vomiting, sleep disturbance, and symptomatic 
orthostasis (11 questions).
The single items of UPDRS Parts I , II, and IV, and the sum scores will be presented in listings. 
The UPDRS Part I V will be presented separately for each item, the sum scores of UPDRS Part I 
and II will be summarized by group, and the change from Baseline to Visit 2 in UPDRS P art II 
score will be anal yzed using ANCOVA as described in Section 8.1.2 .
9 PHA RMACOKINETICS A NDPHA RMACODYNA MICS 
9.1 Pharmacokinetics
Not applicable.
9.2 Pharmacodynamics
Not applicable.
10 SAFETY ANAL YSES
In general, safety  anal yses will be conducted with the SS as randomized.
10.1 Extent of e xposure
The overall duration of exposure is defined as the date of last patch administration minus the date 
of the first pat ch application + 1 day . The overall exposure duration will be summarized using 
descriptive statistics for the subjects. 
10.2 Adverse e vents
Adverse events with start date prior to first administration of study medication are defined as 
pre-treatment AEs. No summaries of these events will be provide d, they  areincluded in listings. 
Treatment emergent AEs are all AEs starting on or after the date of first study medication and up 
to 30 days after the last dose of study  medication. Also AEs with an earlier onset are treatment 
emergent, if the intensity worsened during the treatment period. AEs occurring more than 30 
days after the last dose will not be considered treatment emergent.
For AEs with a partial start date, the imputation rules as described in Section 4.2 will be applied. 
If a start date is completely  missing, then the AE will be considered treatment-emergent unless 
the AE end date is on or before the first date of study  medication. Duration should not be 
calculated if there is missing stop date information.
Treatment emergent adverse events (TEAE) will be tabulated by  MedDRA system organ class 
(SOC ), high level term (HL T) and preferred term ( PT). The number and percentage of subjects 
experiencing each event at least once will be summarized in addition to the number of events. In 
summaries of TEAEs b y relationship and intensity, respectively, the number of events will not be 
presented.REDACTED The overall duration of exposure is defined as the date of last patch administration minus the date 
REDACTED The overall duration of exposure is defined as the date of last patch administration minus the date 
+ 1 dayREDACTED + 1 day . The overall exposure duration will be summarized using REDACTED . The overall exposure duration will be summarized using COPY es will be conducted with the SS as randomized.COPY es will be conducted with the SS as randomized.
This document calculated if there is missing stop date information.
document calculated if there is missing stop date information.
Treatment emergent adverse events 
document Treatment emergent adverse events cannot If a start date is completely
cannot If a start date is completely
the AE end date is on or before 
cannot the AE end date is on or before 
calculated if there is missing stop date information.cannot calculated if there is missing stop date information.be For AEs with a partial start date, the imputation rules as described in be For AEs with a partial start date, the imputation rules as described in 
If a start date is completelybe If a start date is completelyused emergent, if the intensity worsened during the treatment period. AEs occurring more than 30 
used emergent, if the intensity worsened during the treatment period. AEs occurring more than 30 
s after the last dose will not be considered treatment emergent.
used s after the last dose will not be considered treatment emergent.
For AEs with a partial start date, the imputation rules as described in used For AEs with a partial start date, the imputation rules as described in to s after the last dose of study
to s after the last dose of study
emergent, if the intensity worsened during the treatment period. AEs occurring more than 30 to emergent, if the intensity worsened during the treatment period. AEs occurring more than 30 support -treatment AEs. No summaries of these events will be pro
support -treatment AEs. No summaries of these events will be pro
Treatment emergent AEs are all AEs starting on or after the date of first study
support Treatment emergent AEs are all AEs starting on or after the date of first study
s after the last dose of study support s after the last dose of studyany Adverse events with start date prior to first administration of study
any Adverse events with start date prior to first administration of study
-treatment AEs. No summaries of these events will be pro any -treatment AEs. No summaries of these events will be promarketing . The overall exposure duration will be summarized using 
marketing . The overall exposure duration will be summarized using 
vents
marketing vents
Adverse events with start date prior to first administration of studymarketing Adverse events with start date prior to first administration of studyauthorization es will be conducted with the SS as randomized.
authorization es will be conducted with the SS as randomized.
The overall duration of exposure is defined as the date of last patch administration minus the date 
authorization The overall duration of exposure is defined as the date of last patch administration minus the date 
. The overall exposure duration will be summarized using authorization . The overall exposure duration will be summarized using application es will be conducted with the SS as randomized.application es will be conducted with the SS as randomized.and any extensions  group, and the change from Baseline to Visit 2 in UPDRS P
extensions  group, and the change from Baseline to Visit 2 in UPDRS P
MICS 
extensions MICS or y for each item, the sum scores of UPDRS Part I 
or y for each item, the sum scores of UPDRS Part I 
 group, and the change from Baseline to Visit 2 in UPDRS P or  group, and the change from Baseline to Visit 2 in UPDRS P art II or art II variations , II, and IV, and the sum scores will be presented in listings. 
variations , II, and IV, and the sum scores will be presented in listings. 
y for each item, the sum scores of UPDRS Part I variations y for each item, the sum scores of UPDRS Part I thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 26of 39All summaries will be sorted alphabetically  by SOC and HLT and by descending frequency  of 
PT in the Experimental Group within HLTs. If there is more than one PT with the same 
frequency  in the Experimental Group these events will be sorted alphabetically.
Tables showing TEAEs, serious TEAEs, non-serious TEAEs, TEAEs leading to discontinuation 
of study medication , TEAEs by  maximum intensity , TEAEs by maximum relationship, and 
TEAEs including subject numbers will be provided. The table showing AEs leading to stud y 
discontinuation will also be provided for the ES. A glossary  of MedDRA terms and associated 
investigator provided terms for all adverse events will be presented. Individual subject data 
listings will be presented for all AEs, serious TEAEs, TEAEs leading to withdrawal of stud y 
medication , and TEAEs with fatal outcome.
10.3 Clinical laboratory  evaluations
Not applicable.
10.4 Other observations related to safety
10.4.1 Weight
Weight recorded in pounds (lb) will be converted to kilograms (kg) as described in Section 6.1 . 
Summary  statistics of the actual values and change from Baseline values of body weight will be 
presented b y visit in the SS.
10.4.2 Other safety  variables
The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
study  for the Control Group and the Experimental Group is one o f the safety variables. This is 
described in Section 8.1.2 .
REDACTED The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
REDACTED The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
REDACTED for the Control Group and the Experimental Group is one o
REDACTED for the Control Group and the Experimental Group is one oCOPY 
This document cannot be used to support any marketing authorization The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
authorization The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
authorization for the Control Group and the Experimental Group is one o
authorization for the Control Group and the Experimental Group is one oapplication Weight recorded in pounds (lb) will be converted to kilograms (kg) as described in 
application Weight recorded in pounds (lb) will be converted to kilograms (kg) as described in 
 statistics of the actual values and change from Baseline values of body
application  statistics of the actual values and change from Baseline values of bodyand any extensions or wal of studor wal of stud variations  of MedDRA terms and associated 
variations  of MedDRA terms and associated 
investigator provided terms for all adverse events will be presented. Individual subject data variations investigator provided terms for all adverse events will be presented. Individual subject data 
wal of stud variations wal of stud y variations y thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 27of 3911 REFERENCES
Jenkinson C., Fitzpatrick R., Petro V., Greenhall R., and Hyman N. (1997) The Parkinson’s 
Disease Questionnaire (PDQ-39). Development and validation of a Parkinson’s Disease 
summary  index score. Age Ageing, 26:353-357.
Keys A; Fidanza F; Karvonen M; Kimura N; Taylor H. Indices of relative weight and obesity. 
Journal of Chronic Diseases 1972, 25 (6–7): 329–43. 
Mosteller RD. Simplified calculation of body surface area. N Engl J Med 1987 Oct22; 
317(17):1098 (le tter).
Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The Unified 
Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 
2003;18:738-50.
NEUPRO [package insert]. Smy rna, GA: UCB Inc.; 2016
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions  Task Force on Rating Scales for Parkinson’s Disease. The Unified 
extensions  Task Force on Rating Scales for Parkinson’s Disease. The Unified 
Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 
extensions Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 28of 3912 APPENDIC ES
Not applicable.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 29of 3913 AMENDMENT(S) TO THE STA TISTICAL ANAL YSIS PLAN 
(SAP) (IF A PPLICABLE)
13.1 AMENDMENT 1
Rationale for the amendment
The SAP was amended after the Data Evaluation Meeting, to specify the SS more precisel y, to 
define the handling of question 28 of PDQ -39, to describe the derivation of Kinesia-360 scores in 
more detail, and to correct the subgroup level of concomitant medications presented. In addition, 
new Kinesia variables, and the handling of rescreened subjects and of phone contacts has been 
added.
Modifications and changes
Changes in section 2.1
Following text before section 2.1.1 was removed in order to keep this section consistent with the 
clinical study protocol:
A primary  objective of PD0049 is to evaluate whether Parkinson’s disease motor s ymptoms in 
subjects starting Neupro can be improved b y using feedback of motor s ymptom data from the 
Kinesia- 360 wearable technology  presented to subjects and Investigators in addition to standard 
clinical practice as compared with only standard clinical practice. A primary objective is to 
evaluate whether a clinician is more likely to determine a Neupro dosing regimen that improves 
a subject’s Parkinson’s disease motor s ymptoms when using motor s ymptom data collected with 
the Kinesia-360 wearable technology in addition to standard clinical practice as compared with 
only standard clinical practice. Another primary  objective is to evaluate whether subjects with 
Parkinson’s disease are more likely to continue the usage of Neupro if Parkinson’s disease motor 
symptom data collected using the Kinesia wearable technology  is used to provide the subjects 
with feedback on the status of their Parkinson’s disease motor s ymptoms and is used in addition 
to standard of care for titrating their Neupro dosing regimen. Other objectives include to evaluate 
the quality  of life and engagement in the management and treatment of their disease within 
subjects in either group, as well as to evaluate the safet y of Neupro.
Changes in section 2.2.1.1
The primary  efficacy  variables of this study  are:
Change from Baseline (Visit 1/Week 1) to Visit 2 (Week 12/3 months after start of treatment 
with Neupro) in Unified Parkinson’s Disease Rating Scale (UPDRS) Part III Motor Score 
Change from Baseline (Visit 1/Week 1) to Visit 2 (Week 12) in Kinesia-ONE variables:
finger tapping speed score
rest tremor score
averaged finger tapping speed and resting tremor scores
postural tremor score
finger tapping amplitude score
hand grasp speed scoreREDACTED  to determine a Neupro dosing regimen that improves 
REDACTED  to determine a Neupro dosing regimen that improves 
ptoms when using motor s
REDACTED ptoms when using motor s
y in addition to standard clinical practice as compared with 
REDACTED y in addition to standard clinical practice as compared with 
 standard clinical practice. Another primary
REDACTED  standard clinical practice. Another primary
REDACTED  to continue the usage of Neupro if Parkinson’s disease motor REDACTED  to continue the usage of Neupro if Parkinson’s disease motor 
mptom data collected using the Kinesia wearable technologyREDACTED mptom data collected using the Kinesia wearable technologyCOPY  presented to subjects and Investigators in addition to standard 
COPY  presented to subjects and Investigators in addition to standard 
y standard clinical p
COPY y standard clinical p
 to determine a Neupro dosing regimen that improves COPY  to determine a Neupro dosing regimen that improves 
This document cannot Change from Baseline (Visit
cannot Change from Baseline (Visit
cannot finger tapping speed scorecannot finger tapping speed scorebe with Neupro) in Unified Parkinson’s Disease Rating Scale (UPDRS) Partbe with Neupro) in Unified Parkinson’s Disease Rating Scale (UPDRS) Part used efficacy
used efficacy
used Change from Baseline (Visitused Change from Baseline (Visit
with Neupro) in Unified Parkinson’s Disease Rating Scale (UPDRS) Part used with Neupro) in Unified Parkinson’s Disease Rating Scale (UPDRS) Partto efficacyto efficacy  variables of thto  variables of th efficacy  variables of th efficacyto efficacy  variables of th efficacysupport subjects in either group, as well as to evaluate the safet
support subjects in either group, as well as to evaluate the safet
hanges in section 2.2.1.1
support hanges in section 2.2.1.1
 variables of thsupport  variables of thany to standard of care for titrating their Neupro dosing regimen. Other 
any to standard of care for titrating their Neupro dosing regimen. Other 
 of life and engagement in the management and treatment of their disease within any  of life and engagement in the management and treatment of their disease within 
subjects in either group, as well as to evaluate the safet any subjects in either group, as well as to evaluate the safetmarketing  to continue the usage of Neupro if Parkinson’s disease motor 
marketing  to continue the usage of Neupro if Parkinson’s disease motor 
mptom data collected using the Kinesia wearable technology
marketing mptom data collected using the Kinesia wearable technology
with feedback on the status of their Parkinson’s disease motor s
marketing with feedback on the status of their Parkinson’s disease motor s
to standard of care for titrating their Neupro dosing regimen. Other marketing to standard of care for titrating their Neupro dosing regimen. Other authorization y standard clinical p
authorization y standard clinical p
 to determine a Neupro dosing regimen that improves 
authorization  to determine a Neupro dosing regimen that improves 
ptoms when using motor s
authorization ptoms when using motor s
y in addition to standard clinical practice as compared with 
authorization y in addition to standard clinical practice as compared with 
 standard clinical practice. Another primaryauthorization  standard clinical practice. Another primary  objective is to evaluate whether subjects with authorization  objective is to evaluate whether subjects with  standard clinical practice. Another primary  objective is to evaluate whether subjects with  standard clinical practice. Another primaryauthorization  standard clinical practice. Another primary  objective is to evaluate whether subjects with  standard clinical practice. Another primary
 to continue the usage of Neupro if Parkinson’s disease motor authorization  to continue the usage of Neupro if Parkinson’s disease motor application  objective of PD0049 is to evaluate whether Parkinson’s disease motor s
application  objective of PD0049 is to evaluate whether Parkinson’s disease motor s
y using feedback of motor s
application y using feedback of motor s
 presented to subjects and Investigators in addition to standard 
application  presented to subjects and Investigators in addition to standard 
y standard clinical p application y standard clinical p ractice. A primary objective is to application ractice. A primary objective is to and was removed in order to keep this section consistent with the 
and was removed in order to keep this section consistent with the 
 objective of PD0049 is to evaluate whether Parkinson’s disease motor sand  objective of PD0049 is to evaluate whether Parkinson’s disease motor sany was removed in order to keep this section consistent with the any was removed in order to keep this section consistent with the extensions or has been or has been variations 360 scores in 
variations 360 scores in 
In addition, variations In addition, 
has been variations has been thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 30of 39hand grasp amplitude score
rapid alternating movement speed score
rapid alternating amplitude score
dyskinesia score
Neupro dose per 24h at Visit 2 (Week 12) 
Number of Neupro dose changes during the stud y (between Visit 1 and Visit 2) 
Discontinuation of treatment with Neupro during the course of the study
Has been changed to:
The primary  efficacy  variables of this study  are:
Change from Baseline (Visit 1/Week 1) to Visit 2 (Week 12/3 months after start of treatment 
with Neupro) in Unified Parkinson’s Disease Rating Scale (UPDRS) Part III Motor Score 
Change from Baseline (Visit 1/Week 1) to Visit 2 (Week 12) in Kinesia-ONE variables:
finger tapping speed score
rest tremor score
averaged finger tapping speed and resting tremor scores
postural tremor score
finger tapping amplitude score
hand grasp speed score
hand grasp amplitude score
rapid alternating movement speed score
rapid alternating amplitude score
dyskinesia score
kinetic tremor score
rapid alternating movement rhythm score
hand movements rhythm score
finger tapping rhythm score
average Kinesia- ONE score
Neupro dose per 24h at Visit 2 (Week 12) 
Number of Neupro dose changes during the stud y (between Visit 1 and Visit 2) 
Discontinuation of treatment with Neupro during the course of the study
Changes in section 2.2.1.2
Other efficacy  varibles are:REDACTED COPY averaged finger tapping speed and resting tremor scoresCOPY averaged finger tapping speed and resting tremor scores
This document 
document cannot finger tapping rhythm score
cannot finger tapping rhythm score
cannot be hand movements rhythm scorebe hand movements rhythm scoreused rapid alternating movement rhythm score
used rapid alternating movement rhythm score
hand movements rhythm scoreused hand movements rhythm scoreto kinetic tremor scoreto kinetic tremor score support rapid alternating amplitude score
support rapid alternating amplitude score
kinetic tremor score support kinetic tremor scoreany rapid alternating movement speed score
any rapid alternating movement speed score
rapid alternating amplitude score any rapid alternating amplitude scoremarketing rapid alternating movement speed score marketing rapid alternating movement speed scoreauthorization averaged finger tapping speed and resting tremor scores
authorization averaged finger tapping speed and resting tremor scoresapplication 12) in Kinesia
application 12) in Kinesia
averaged finger tapping speed and resting tremor scoresapplication averaged finger tapping speed and resting tremor scoresand with Neupro) in Unified Parkinson’s Disease Rating Scale (UPDRS) Part
and with Neupro) in Unified Parkinson’s Disease Rating Scale (UPDRS) Part
12) in Kinesia and 12) in Kinesiaany months after start of treatment 
any months after start of treatment 
with Neupro) in Unified Parkinson’s Disease Rating Scale (UPDRS) Part any with Neupro) in Unified Parkinson’s Disease Rating Scale (UPDRS) Partextensions months after start of treatment extensions months after start of treatment or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 31of 39Change from Baseline to Visit 2 in the motor scores derived from the Kinesia-360 wearable 
technology  by time (weekly /monthly ) for the Experimental Group in:
average daily tremor score
average daily slowness score
average dail y dyskinesia score
percent wear -time tremor detected
percent wear- time dy skinesia detected
percent wear- time user not moving
percent wear-time user was walking score
percent wear-time user active but not walking
number of steps per hour while wearing device
Change from Baseline to Visit 2 (Week 12) in the 39- Item Parkinson’s Disease 
Questionnaire (PDQ -39) scores.
Change from Baseline to Visit 2 (Week 12) in subject engagement questionnaire scores.
Has been changed to:
Other efficacy  varibles are:
Change from Baseline to Visit 2 in the motor scores derived from the Kinesia-360 wearable 
technology  by time (weekly /monthly ) for the Experimental Group in:
average daily tremor score
average daily slowness score
average dail y dyskinesia score
percent wear-time tremor detected
percent wear- time dyskinesia detected
percent wear- time user not moving
percent wear-time user was walking score
percent wear-time user active but not walking
number of steps per hour while wearing device
Number of days on Kinesia-360 device
Change from Baseline to Visit 2 (Week 12) in the 39- Item Parkinson’s Disease 
Questionnaire (PDQ -39) scores.
Change from Baseline to Visit 2 (Week 12) in subject engagement questionnaire scores.
Changes in section 3.1
Following sentences were added to the penultimate paragraph of section 3.1:REDACTED 2 in the moto
REDACTED 2 in the moto
/monthly
REDACTED /monthly ) for the Experimental Group in:
REDACTED ) for the Experimental Group in:COPY 12) in subject engagement questionnaire scores.
COPY 12) in subject engagement questionnaire scores.
This document Number of days on Kinesia
document Number of days on Kinesia

document cannot percent wear
cannot percent wear
number of steps per hour while wearing device
cannot number of steps per hour while wearing device
Number of days on Kinesiacannot Number of days on Kinesiabe percent wearbe percent wearused percent wear
used percent wear
percent wearused percent wearto percent wear to percent wear -to -time user not movingto time user not movingsupport time tremor detected
support time tremor detected
time support time dysupport dy
time user not movingsupport time user not movingany kinesia score
any kinesia score
time tremor detectedany time tremor detectedmarketing y slowness score
marketing y slowness score
kinesia scoremarketing kinesia scoreauthorization 2 in the moto
authorization 2 in the moto r scores derived from the Kinesia
authorization r scores derived from the Kinesia
) for the Experimental Group in:authorization ) for the Experimental Group in:application em Parkinson’s Disease 
application em Parkinson’s Disease 
12) in subject engagement questionnaire scores.
application 12) in subject engagement questionnaire scores.and em Parkinson’s Disease and em Parkinson’s Disease any extensions or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 32of 39The visit dates and phone contact dates will be presented in a listing. This includes the scheduled 
phone contacts in the Experimental Group and the unscheduled phone contacts in both groups. 
As scheduled phone contacts in the Experimental Group were consistentl y reported on both the 
form for scheduled contacts as well as on the unscheduled telephone log, duplicate phone 
contacts will be removed at the SDTM level. It will be considered at the SDTM level that the 
scheduled phone contacts do not appear t wice, unless two or more phone contacts were 
documented as conducted on the same day.
Changes in section 3.2
Following subsection 3.2.4 was added at the end of section 3.2:
3.2.4 Rescreening
Rescreening was not foreseen in the clinical stud y protocol. Howe ver one subject was 
rescreened. In this case, the initial screening is documented with a different subject number than 
the second screening and following visits of this same subject. The fact that a rescreened subject 
has 2 different subject numbers is not accounted for in the anal ysis, which means that the subject 
willbe counted twice in the tables based on the Enrolled Set. This was decided to be acceptable 
due to the exploratory  nature of this study, and will not impact the efficacy  and safet y analysis.
Changes in section 3.5.2
The SS will consist of all subjects who received at least 1 dose of Neupro. The SS will be used 
for the analy sis of all demographic, disposition, and safet y data.
Has been changed to:
The SS will consist of all subjects who received at least 1 dose of Neupro. A subject who 
received Neupro after screen fail ingis not considered as treated within the study and 
therefore not included in the SS. The SS will be used for the anal ysis of all demographic, 
disposition, and safety  data.
Changes in section 3.9
Not applicable.
Has been changed to:
Additional Kinesia -ONE scores which were not prespecified in the clinical study protocol 
are provided by the vendor. These will be analyzed in the same way as the prespecified 
variables.
Changes in section 5.1
The following listings will be provided: study eligibility  criteria text, subjects who did not meet 
study  eligibility  criteria, subject disposition, subject anal ysis sets, study discontinuation and visit 
dates.
Has been changed to:
The following listings will be provided: study eligibility  criteria text, subjects who did not meet 
study  eligibility  criteria, subject disposition, subject anal ysis sets, Neupro discontinuation and 
visit dates.
Changes in section 6.1REDACTED sis of all demographic, disposition, and safet
REDACTED sis of all demographic, disposition, and safet
The SS will consist of all subjects who receiv
REDACTED The SS will consist of all subjects who receiv
ingREDACTED ingis not considered as treated within the study and REDACTED is not considered as treated within the study and 
The SS will be used for the analREDACTED The SS will be used for the analCOPY The SS will consist of all subjects who received at least 1 dose of Neupro. The SS will be used 
COPY The SS will consist of all subjects who received at least 1 dose of Neupro. The SS will be used 
sis of all demographic, disposition, and safet COPY sis of all demographic, disposition, and safet
This document study
document study
dates.
document dates.cannot hanges in section 
cannot hanges in section 
The following listings will be provided: 
cannot The following listings will be provided: 
studycannot study  eligibilitycannot  eligibility study  eligibility studycannot study  eligibility studybe hanges in section be hanges in section used are provided by the vendor. These will be analyzed in the same way as the prespecified 
used are provided by the vendor. These will be analyzed in the same way as the prespecified to Additional Kinesiato Additional Kinesia -to -ONE scores which were not prespecified in the clinical study protocol to ONE scores which were not prespecified in the clinical study protocol 
are provided by the vendor. These will be analyzed in the same way as the prespecified to are provided by the vendor. These will be analyzed in the same way as the prespecified support ONE scores which were not prespecified in the clinical study protocol support ONE scores which were not prespecified in the clinical study protocol any marketing is not considered as treated within the study and 
marketing is not considered as treated within the study and 
The SS will be used for the anal
marketing The SS will be used for the analauthorization The SS will consist of all subjects who received at least 1 dose of Neupro. The SS will be used 
authorization The SS will consist of all subjects who received at least 1 dose of Neupro. The SS will be used 
sis of all demographic, disposition, and safet
authorization sis of all demographic, disposition, and safet y data.
authorization y data.
The SS will consist of all subjects who receivauthorization The SS will consist of all subjects who receiv ed at least 1 dose of Neupro. authorization ed at least 1 dose of Neupro. 
is not considered as treated within the study and authorization is not considered as treated within the study and application This was decided to be acceptable 
application This was decided to be acceptable 
, and will not impact the efficacy
application , and will not impact the efficacy
The SS will consist of all subjects who received at least 1 dose of Neupro. The SS will be used application The SS will consist of all subjects who received at least 1 dose of Neupro. The SS will be used and is, wh
and is, wh ich means that the subject 
and ich means that the subject 
This was decided to be acceptable and This was decided to be acceptable any In this case, the initial screening is documented with a different subject number than 
any In this case, the initial screening is documented with a different subject number than 
the second screening and following visits of this same subject. The fact that a rescreened subject any the second screening and following visits of this same subject. The fact that a rescreened subject 
ich means that the subject any ich means that the subject extensions subject was 
extensions subject was 
In this case, the initial screening is documented with a different subject number than extensions In this case, the initial screening is documented with a different subject number than or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 33of 39The calculation of age is based on the date of informed consent and the date of birth. If the date 
of birth is incomplete, it will be completed with January as imputed month if month is missing 
and it will be completed with 1 as imputed day  of birth if day  is missing. Age is calculated as 
follows: Age (y ears) = ([Date of Informed Consent] – [Imputed Date of Birth]) / 365.25. It will 
be summarized as a continuous variable and as a categorical variable based on the categories: <65 y ears, ≥65 y ears, and also based on the categories: <75 years, ≥75 y ears.
Has been changed to:
The calculation of age is based on the date of informed consent and the date of birth. If the date 
of birth is incomplete, it will be completed with January as imputed month if month is missing 
and it will be completed with 1 as imputed day  of birth if day  is missing. Age is calculated as 
follows: Age (y ears) = ([Date of Informed Consent] – [Imputed Date of Birth]) / 365.25. It will 
be summarized as a continuous variable and as a categorical variable based on the categories: 
<65 years, 65- <85 years, ≥85 years, also based on the categories: <65 years, ≥65 y ears, and also 
based on the categories: <75 years, ≥75 y ears.
Changes in section 6.4
Prior and concomitant medications will be summarized separatel y for the SS. The number and 
percentage of subjects who used prior and concomitant medications, respectivel y, will be 
presented according to the anatomical main group (level  1), the pharmacological subgroup (level 
2), and the preferred term.
Has been changed to:
Prior and concomitant medications will be summarized separatel y for the SS. The number and 
percentage of subjects who used prior and concomitant medications, respectivel y, will be 
presented according to the anatomical main group (level 1), the pharmacological subgroup 
(level 3), and the preferred term.
Changes in section 8.1.1.2
The Kinesia-ONE data includes the following variables collected at Baseline and at Visit 2:
finger tapping speed score
rest tremor score
averaged finger tapping speed and resting tremor s cores
postural tremor score
finger tapping amplitude score
hand grasp speed score
hand grasp amplitude score
rapid alternating movement speed score
rapid alternating amplitude score
dyskinesia scoreREDACTED and concomitant medications will be summarized separatel
REDACTED and concomitant medications will be summarized separatel
percentage of subjects who used prior and concomitant medications, respectivel
REDACTED percentage of subjects who used prior and concomitant medications, respectivel
presented according to the anatomical main group (level 1), the pharmacological suREDACTED presented according to the anatomical main group (level 1), the pharmacological suCOPY presented according to the anatomical main group (level  1), the pharmacological subgroup (level 
COPY presented according to the anatomical main group (level  1), the pharmacological subgroup (level 
This document 
document hand grasp amplitude score
document hand grasp amplitude scorecannot finger tapping amplitude score
cannot finger tapping amplitude score
hand grasp speed scorecannot hand grasp speed scorebe postural tremor score
be postural tremor score
finger tapping amplitude score be finger tapping amplitude scoreused averaged finger tapping speed and resting tremor s
used averaged finger tapping speed and resting tremor s
postural tremor score used postural tremor scoreto averaged finger tapping speed and resting tremor s to averaged finger tapping speed and resting tremor ssupport finger tapping speed score
support finger tapping speed scoreany -ONE data includes the following variables collected at Baseline and at Visit 2:any -ONE data includes the following variables collected at Baseline and at Visit 2:marketing presented according to the anatomical main group (level 1), the pharmacological su
marketing presented according to the anatomical main group (level 1), the pharmacological suauthorization and concomitant medications will be summarized separatel
authorization and concomitant medications will be summarized separatel
percentage of subjects who used prior and concomitant medications, respectivelauthorization percentage of subjects who used prior and concomitant medications, respectivel
presented according to the anatomical main group (level 1), the pharmacological suauthorization presented according to the anatomical main group (level 1), the pharmacological suapplication Prior and concomitant medications will be summarized separatel
application Prior and concomitant medications will be summarized separatel y 
application y for the SS. 
application for the SS. 
percentage of subjects who used prior and concomitant medications, respectivel
application percentage of subjects who used prior and concomitant medications, respectivel
presented according to the anatomical main group (level  1), the pharmacological subgroup (level 
application presented according to the anatomical main group (level  1), the pharmacological subgroup (level and any ars, 
any ars, extensions  as imputed month if month is missing 
extensions  as imputed month if month is missing 
 is missing. Age is calculated as 
extensions  is missing. Age is calculated as 
mputed Date of Birth]) / 365.25. I
extensions mputed Date of Birth]) / 365.25. I
based on the 
extensions based on the 
ars, extensions ars, ≥65 yextensions ≥65 yor The calculation of age is based on the date of informed consent and the date of birth. If the date 
or The calculation of age is based on the date of informed consent and the date of birth. If the date 
 as imputed month if month is missing or  as imputed month if month is missing variations The calculation of age is based on the date of informed consent and the date of birth. If the date variations The calculation of age is based on the date of informed consent and the date of birth. If the date thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 34of 39These scores are all calculated as an average from triplicate repeated assessments at a 
measurement point. 
Has been changed to:
The Kinesia-ONE data includes the following variables collected at Baseline and at Visit 2:
finger tapping speed score
rest tremor score
averaged finger tapping speed and resting tremor scores
postural tremor score
finger tapping amplitude score
hand grasp speed score
hand grasp amplitude score
rapid alternating movement speed score
rapid alternating amplitude score
dyskinesia score
kinetic tremor score
rapid alternating movement rhythm score
hand movements rhythm score
finger tapping rhythm score 
These scores are all calculated as an average from triplicate repeated assessments at a 
measurement point. 
In addition, a composite Kinesia-ONE score will be calculated as the average o f following 
scores: 
finger tapping speed score
rest tremor score
postural tremor score
kinetic tremor score
finger tapping amplitude score
finger tapping rhythm score
hand grasp speed score
hand grasp amplitude score
hand grasp rhythm score
rapid alternating movement speed scoreREDACTED rhythm score
REDACTED rhythm scoreCOPY 
This document finger tapping rhythm score
document finger tapping rhythm score

document cannot kinetic tremor score
cannot kinetic tremor score
finger tapping amplitude score
cannot finger tapping amplitude score
finger tapping rhythm scorecannot finger tapping rhythm scorebe kinetic tremor score be kinetic tremor scoreused rest tremor score
used rest tremor score
postural tremor scoreused postural tremor scoreto rest tremor score to rest tremor scoresupport finger tapping speed score
support finger tapping speed scoreany In addition, a composite Kinesia-ONE score will be calculated as the average oany In addition, a composite Kinesia-ONE score will be calculated as the average omarketing These scores are all calculated as an average from triplicate
marketing These scores are all calculated as an average from triplicateauthorization application and any extensions or variations thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 35of 39rapid alternating amplitude score
rapid alternating rhythm score
The composite score will only be calculated if at least 50% of the scores are available.
Changes in section 8.1.2
The Neupro dose per 24h at Visit 2 will be summarized by group, as well as the Neupro starting 
dose per 24h. Both assessments of Neupro dose will be related in a shift table by  group.
The number of Neupro dose changes after first administration until Visit 2 will be summarized 
by group.
The comparison of the rate of discontinuation of treatment with Neupro during the course of the study  for the control group and the experimental group will be performed using logistic 
regression with factors for treatment a nd center .
Has been changed to:
The Neupro dose per 24h at Visit 2 will be summarized by group, as well as the Neupro starting 
dose per 24h. Both assessments of Neupro dose will be related in a shift table by  group. In 
addition, Neupro dose and Neupro dose change will be tabulated as continuous variable.
The number of Neupro dose changes after first administration until Visit 2 will be summarized 
by group.
The comparison of the rate of discontinuation of treatment with Neupro during the course of the study  for the control group and the experimental group will be performed using logistic 
regression with factors for treatment and center.
Changes in section 8.2.1
Kinesia-360- based efficacy  data will be presented descriptivel y for the Experimental Group. Due 
to repeated measurements (during titration weekly and during maintenance), comparisons will be 
performed b y time point and also by dose, if applicable (dependent on number of subjects in 
respective dose groups). Optional time points might also be subject to a nalysis (dependent on 
number of subjects at respective time points or windows for time points).
Change from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores 
derived from the Kinesia-360 wearable technology  by Neupro dose level (mg/24h) for the 
Experimental Group will be summarized for following scores:
average daily tremor score
average daily slowness score
average dail y dyskinesia score
percent wear-time tremor detected
percent wear- time dy skinesia detected
percent wear- time user not moving
percent wear-time user was walking scoreREDACTED The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
REDACTED The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
for the control group and the experimental group will be performed using 
REDACTED for the control group and the experimental group will be performed using 
regression with factors for treatment and center
REDACTED regression with factors for treatment and centerCOPY after first administration until Visit 2 will be summarized 
COPY after first administration until Visit 2 will be summarized 
This document average dail
document average dail

document cannot average dail
cannot average dail
average dail
cannot average dail
average dailcannot average dailbe average dailbe average dailused derived from the Kinesia
used derived from the Kinesia
Experimental Group will be summarized for following scores:used Experimental Group will be summarized for following scores:to Change from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores 
to Change from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores 
derived from the Kinesia to derived from the Kinesiasupport respective dose groups). Optional time points might also be subject to a
support respective dose groups). Optional time points might also be subject to a
number of subjects at respective time points or windows for time points).
support number of subjects at respective time points or windows for time points).
Change from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores support Change from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores any y time point and also by dose, if applicable (dependent on number of subjects in any y time point and also by dose, if applicable (dependent on number of subjects in 
respective dose groups). Optional time points might also be subject to a any respective dose groups). Optional time points might also be subject to amarketing  data will be presented descriptivel
marketing  data will be presented descriptivel
repeated measurements (during titration weeklmarketing repeated measurements (during titration weekl
y time point and also by dose, if applicable (dependent on number of subjects in marketing y time point and also by dose, if applicable (dependent on number of subjects in authorization The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
authorization The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
for the control group and the experimental group will be performed using 
authorization for the control group and the experimental group will be performed using 
regression with factors for treatment and centerauthorization regression with factors for treatment and center .authorization .application  group, as well as the Neupro starting 
application  group, as well as the Neupro starting 
dose per 24h. Both assessments of Neupro dose will be related in a shift table by
application dose per 24h. Both assessments of Neupro dose will be related in a shift table by
change will be tabulated as continuous variable.
application change will be tabulated as continuous variable.
after first administration until Visit 2 will be summarized application after first administration until Visit 2 will be summarized and  group, as well as the Neupro starting and  group, as well as the Neupro starting any extensions The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
extensions The comparison of the rate of discontinuation of treatment with Neupro during the course of the 
 for the control group and the experimental group will be performed using 
extensions  for the control group and the experimental group will be performed using logistic 
extensions logistic or t 2 will be summarized 
or t 2 will be summarized variations  group, as well as the Neupro starting 
variations  group, as well as the Neupro starting 
t 2 will be summarized variations t 2 will be summarized thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 36of 39percent wear-time user active but not walking
number of steps per hour while wearing device
The scores will be averaged from 2 consecutive days of wearing in the respective assessment 
week. Assessments on study  day 8 to 14 are eligible for Week 2 scores, assessments on study 
day 15 to 21 are eligible for Week 3 scores, assessments on study  day 22 to 28 are eligible for 
Week 4 scores, assessments on study  day 43 to 56 are eligible for Week 7/8 scores, and 
assessments on study  day 71 to 77 are eligible for Week 11 assessments. The Week 7/8 is an 
artificially  added Week, which considers the data collected on voluntary  basis during that time 
interval, and therefore might have sparse data. If more than 2 consecutive assessments are available for Week 7/8, the latest 2 consecutive values will be considered. The same applies for the assessments in Week 2, Week 3, Week 4, and Week 11: If more than 2 consecutive 
assessments are available per week, the latest 2 consecutive values will be considered.
Has been changed to:Kinesia-360- based efficacy  data will be presented descriptivel y for the Experimental Group. Due 
to repeated measurements (during titration weekly and during maintenance), comparisons will be 
performe d by time point and also by  dose, if applicable (dependent on number of subjects in 
respective dose groups). Optional time points might also be subject to analysis (dependent on 
number of subjects at respective time points or windows for time points).
Change from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores 
derived from the Kinesia-360 wearable technology  by Neupro dose level (mg/24h) for the 
Experimental Group will be summarized for following scores:
average daily tremor sc ore
average daily slowness score
average dail y dyskinesia score
percent wear-time tremor detected
percent wear- time dy skinesia detected
percent wear- time user not moving
percent wear-time user was walking score
percent wear-time user active but not walking
number of steps per hour while wearing device
The average daily scores of tremor, slowness and dyskinesia will be derived from the 2-
minutes interval data. Only those 2-minutes interval data records, when the device was not 
paused, will be considered. For each day, starting at 0:00 until 23:58, the available non-paused 2-minutes interval scores of tremor (and similarly for slowness and dyskinesia) will 
be selected and the arithmetic mean of these will be calculated which results in the average 
daily scores. 
The percent wear-times and number of steps per hour will be derived from the daily 
Kinesia-360 data. Multiple records per day will be averaged and weighted by wear- time.REDACTED ge from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores 
REDACTED ge from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores 
360 wearable technology
REDACTED 360 wearable technology
REDACTED Experimental Group will be summarized for following scores:
REDACTED Experimental Group will be summarized for following scores:COPY number of subjects at respective time points or windows for time points).
COPY number of subjects at respective time points or windows for time points).
ge from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores COPY ge from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores 
360 wearable technologyCOPY 360 wearable technology
This document minutes interval data. Only those 2
document minutes interval data. Only those 2
document paused, will be considered. For
document paused, will be considered. For
paused 2
document paused 2cannot number of steps per hour while wearing device
cannot number of steps per hour while wearing device
The average daily scores of tremor, slowness and dyskinesia will be derived from the 2
cannot The average daily scores of tremor, slowness and dyskinesia will be derived from the 2
minutes interval data. Only those 2cannot minutes interval data. Only those 2be percent wear
be percent wear
number of steps per hour while wearing device be number of steps per hour while wearing deviceused time user was walking score
used time user was walking score
percent wearused percent wear -used -time user active but not walkingused time user active but not walkingto time user was walking scoreto time user was walking scoresupport skinesia detected
support skinesia detected
time user not movingsupport time user not movingany time tremor detected
any time tremor detected
skinesia detectedany skinesia detectedmarketing time tremor detectedmarketing time tremor detectedauthorization ge from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores 
authorization ge from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores 
360 wearable technology
authorization 360 wearable technology  by
authorization  by 360 wearable technology  by 360 wearable technology
authorization 360 wearable technology  by 360 wearable technology
authorization  Neupro dose level (mg/24h) for the 
authorization  Neupro dose level (mg/24h) for the  by Neupro dose level (mg/24h) for the  by
authorization  by Neupro dose level (mg/24h) for the  by
Experimental Group will be summarized for following scores:
authorization Experimental Group will be summarized for following scores:application y and during maintenance), comparisons will be 
application y and during maintenance), comparisons will be 
 dose, if applicable (dependent on number of subjects in 
application  dose, if applicable (dependent on number of subjects in 
respective dose groups). Optional time points might also be subject to analysis (dependent on 
application respective dose groups). Optional time points might also be subject to analysis (dependent on 
number of subjects at respective time points or windows for time points).application number of subjects at respective time points or windows for time points).
ge from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores application ge from Baseline to Week 2, Week 3, Week 4, Week 7/8, and Week 11 in the motor scores and y for the Experimental Group. Due 
and y for the Experimental Group. Due 
y and during maintenance), comparisons will be and y and during maintenance), comparisons will be any y for the Experimental Group. Due any y for the Experimental Group. Due extensions ecutive assessments are 
extensions ecutive assessments are 
available for Week 7/8, the latest 2 consecutive values will be considered. The same applies for 
extensions available for Week 7/8, the latest 2 consecutive values will be considered. The same applies for 
the assessments in Week 2, Week 3, Week 4, and Week 11: If more than 2 consecutive 
extensions the assessments in Week 2, Week 3, Week 4, and Week 11: If more than 2 consecutive 
secutive values will be considered.
extensions secutive values will be considered.or  basis during that time 
or  basis during that time 
ecutive assessments are or ecutive assessments are variations  day 71 to 77 are eligible for Week 11 assessments. The Week 7/8 is an 
variations  day 71 to 77 are eligible for Week 11 assessments. The Week 7/8 is an 
 basis during that time variations  basis during that time thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 37of 39These daily scores will be used to derive the scores per visit week. The daily scores will be 
averaged from 2 consecutive days of wearing in the respective assessment week. Assessments on 
study  day 8 to 14 are eligible for Week 2 scores, assessments on study  day 15 to 21 are eligible 
for Week 3 scores, assessments on study  day 22 to 28 a re eligible for Week 4 scores, 
assessments on study  day 43 to 56 are eligible for Week 7/8 scores, and assessments on study 
day 71 to 77 are eligible for Week 11 assessments. The Week 7/8 is an artificially added Week, 
which considers the data collected on voluntary  basis during that time interval, and therefore 
might have sparse data. If more than 2 consecutive assessments are available for Week 7/8, the 
latest 2 consecutive values will be considered. The same applies for the assessments in Week 2, 
Week 3, Week 4, and Week 11: If more than 2 consecutive assessments are available per week, the latest 2 consecutive values will be considered.
In addition, the maximum relative day of Kinesia-360 usage will be listed, and the number 
of days the subject used the Kinesia-360 device will be calculated by subject and summarized .
Changes in section 8.2.2
The Parkinson’s Disease Questionnaire (PDQ-39; Jenkinson, 1997) is a simple questionnaire that 
assesses health related quality  of life in individuals with PD. The answer categories are coded as 
follows: 0=never, 1=occasionally , 2=sometimes, 3=often, 4=alway s or cannot do at all. I t 
provides scores in 8 scales: mobility  (questions 1-10), activities of dail y living (questions 11 -16), 
emotions (questions 17- 22), stigma (questions 23 -26), social support (questions 27-29), 
cognition (questions 30-33), communication (questions 24- 36), and bodily  discomfort (questions 
37-39). It is designed for self- completion by  subjects and should take onl y a few minutes for the 
subject to complete. 
For each of the 8 domains a score will be calculated: The coded answer categories of the 
corresponding domain questions will be added. This domain raw value will be multiplied with 100 and divided by the maximum domain raw value (e.g. 4*10=40 for the 10 questions of 
mobility  domain). This transformation gives domain scores between 0 and 100. 
Domain scores will only be calculated if at least 50% of items on the scale have been answered. 
If this is the case, the missing items, if an y, will be repla ced with the overall mean of the item, 
and the corresponding domain score will be calculated based on the replaced questions. 
Has been changed to:The Parkinson’s Disease Questionnaire (PDQ-39; Jenkinson, 1997) is a simple questionnaire that 
assesses heal th related quality  of life in individuals with PD. The answer categories are coded as 
follows: 0=never, 1=occasionally , 2=sometimes, 3=often, 4=alway s or cannot do at all. I t 
provides scores in 8 scales: mobility  (questions 1-10), activities of dail y living (questions 11- 16), 
emotions (questions 17-22), stigma (questions 23-26), social support (questions 27-29), 
cognition (questions 30- 33), communication (questions 34-36), and bodily  discomfort (questions 
37-39). It is designed for self- completion by subjec ts and should take onl y a few minutes for the 
subject to complete. 
For each of the 8 domains a score will be calculated: The coded answer categories of the 
corresponding domain questions will be added. This domain raw value will be multiplied with REDACTED 33), communication (questions 24
REDACTED 33), communication (questions 24
completion by
REDACTED completion by  subjects and should take onl
REDACTED  subjects and should take onl completion by  subjects and should take onl completion by
REDACTED completion by  subjects and should take onl completion by
For each of the 8 domains a score will be calculated: The coded answer categories of the REDACTED For each of the 8 domains a score will be calculated: The coded answer categories of the COPY , 2=sometimes, 3=often, 4=alway
COPY , 2=sometimes, 3=often, 4=alway
10), activities of dail
COPY 10), activities of dail
uestions 23COPY uestions 23 -COPY -26), social support (questions 27COPY 26), social support (questions 27
This document emotions (questions 17
document emotions (questions 17
cognition (questions 30
document cognition (questions 30
37
document 37cannot follows: 0=never, 1=occasionally
cannot follows: 0=never, 1=occasionally
provides scores in 8 scales: mobility
cannot provides scores in 8 scales: mobility
emotions (questions 17cannot emotions (questions 17be The Parkinson’s Disease Questionnaire (PDQ
be The Parkinson’s Disease Questionnaire (PDQ
assesses healbe assesses heal th related qualitybe th related quality
follows: 0=never, 1=occasionallybe follows: 0=never, 1=occasionallyused Has been changed to:
used Has been changed to:
The Parkinson’s Disease Questionnaire (PDQused The Parkinson’s Disease Questionnaire (PDQ
th related qualityused th related qualityto Has been changed to: to Has been changed to:support  be calculated if at least 50% of items on the scale have been answered. 
support  be calculated if at least 50% of items on the scale have been answered. 
If this is the case, the missing items, if an
support If this is the case, the missing items, if an
and the corresponding domain score will be calculated based on the replaced questions. support and the corresponding domain score will be calculated based on the replaced questions. any  domain). This transformation gives domain scores between 0 and 100. 
any  domain). This transformation gives domain scores between 0 and 100. 
 be calculated if at least 50% of items on the scale have been answered. any  be calculated if at least 50% of items on the scale have been answered. marketing For each of the 8 domains a score will be calculated: The coded answer categories of the 
marketing For each of the 8 domains a score will be calculated: The coded answer categories of the 
marketing corresponding domain questions will be added. This domain raw value will be multiplied with 
marketing corresponding domain questions will be added. This domain raw value will be multiplied with 
 the maximum domain raw value (e.g. 4*10=40 for
marketing  the maximum domain raw value (e.g. 4*10=40 for
 domain). This transformation gives domain scores between 0 and 100. marketing  domain). This transformation gives domain scores between 0 and 100. authorization 10), activities of dail
authorization 10), activities of dail
26), social support (questions 27
authorization 26), social support (questions 27
33), communication (questions 24
authorization 33), communication (questions 24
 subjects and should take onl
authorization  subjects and should take onl
For each of the 8 domains a score will be calculated: The coded answer categories of the authorization For each of the 8 domains a score will be calculated: The coded answer categories of the application 39; Jenkinson, 1997) is a simple questionnaire that 
application 39; Jenkinson, 1997) is a simple questionnaire that 
 of life in individuals with PD. The ans
application  of life in individuals with PD. The ans
, 2=sometimes, 3=often, 4=alway
application , 2=sometimes, 3=often, 4=alway
10), activities of dailapplication 10), activities of dail
26), social support (questions 27application 26), social support (questions 27and 39; Jenkinson, 1997) is a simple questionnaire that and 39; Jenkinson, 1997) is a simple questionnaire that any extensions Week 4, and Week 11: If more than 2 consecutive assessments are available per week, 
extensions Week 4, and Week 11: If more than 2 consecutive assessments are available per week, 
360 usage will be listed, and the number 
extensions 360 usage will be listed, and the number 
-360 device will be calculated by subject and extensions -360 device will be calculated by subject and or latest 2 consecutive values will be considered. The same applies for the assessments in Week 2, 
or latest 2 consecutive values will be considered. The same applies for the assessments in Week 2, 
Week 4, and Week 11: If more than 2 consecutive assessments are available per week, or Week 4, and Week 11: If more than 2 consecutive assessments are available per week, variations might have sparse data. If more than 2 consecutive assessments are available for Week 7/8, the 
variations might have sparse data. If more than 2 consecutive assessments are available for Week 7/8, the 
latest 2 consecutive values will be considered. The same applies for the assessments in Week 2, variations latest 2 consecutive values will be considered. The same applies for the assessments in Week 2, thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 38of 39100 and divided by the maximum domain raw value (e.g. 4*10=40 for the 10 questions of 
mobility  domain). This transformation gives domain scores between 0 and 100. 
Domain scores will only be calculated if at least 50% of items on the scale have been answer ed. 
If this is the case, the missing items, if any, will be replaced with the overall mean of the item, and the corresponding domain score will be calculated based on the replaced questions. 
The social support domain consists of questions 27, 28, and 29. If respondents indicate that 
they do not have a spouse or partner on question 28 then social support will be calculated as follows: social support = (sum of questions 27 + 29) / (4 * 2) * 100.
13.2 AMENDMENT 2
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations If respondents indicate that 
variations If respondents indicate that 
they do not have a spouse or partner on question 28 then social support will be calculated 
variations they do not have a spouse or partner on question 28 then social support will be calculated thereof. 
UCB 31 Jan 2018
Statistical Analysis Plan Rotigotine transdermal system PD0049
Confidential Page 39of 39STATISTICA L ANALYSIS PLAN SIGNA TURE P AGE
This document has been reviewed and approved per the Review and Approval of Clinical 
Documents Standard Operating Procedures. Signatures indicate that the final version of the 
Statistical Analy sis Plan (SAP) or amended SAP is released for execution.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 